University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Doctoral Dissertations

Graduate School

12-2004

Growth Stimulation of Pulmonary Adenocarcinoma and their Cells
of Origin by "Chemopreventive" Agents that Increase Intracellular
cAMP
Hussein Abdulhadi Nasser Al-Wadei
University of Tennessee, Knoxville

Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss
Part of the Veterinary Medicine Commons

Recommended Citation
Al-Wadei, Hussein Abdulhadi Nasser, "Growth Stimulation of Pulmonary Adenocarcinoma and their Cells
of Origin by "Chemopreventive" Agents that Increase Intracellular cAMP. " PhD diss., University of
Tennessee, 2004.
https://trace.tennessee.edu/utk_graddiss/4531

This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee
Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized
administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact
trace@utk.edu.

To the Graduate Council:
I am submitting herewith a dissertation written by Hussein Abdulhadi Nasser Al-Wadei entitled
"Growth Stimulation of Pulmonary Adenocarcinoma and their Cells of Origin by
"Chemopreventive" Agents that Increase Intracellular cAMP." I have examined the final electronic
copy of this dissertation for form and content and recommend that it be accepted in partial
fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in
Comparative and Experimental Medicine.
Hildegard M. Schuller, Major Professor
We have read this dissertation and recommend its acceptance:
Potgieter L.N.D, Michael D. Karlstad, Howard K. Plummer
Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)

To the Graduate Council:
I am submitting herewith a dissertation written by Hussein Abdulhadi Nasser Al-Wadei
entitled "Growth Stimulation of Pulmonary Adenocarcinoma and their Cells of Origin by
"Chemopreventive" Agents that Increase Intracellular cAMP." I have examined the final
paper copy of this dissertation for form and content and recommend that it be accepted in
partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a
major in Comparative and Experimental Medicine.

Hildegard M. Schuller, Major Professor

We have read this dissertation

�FL±e7�

Michael D. Karlstad

Howard K. Plummer
Accepted for the Council:

C:-

Vice Chane

�},)
ean of

-rr;e6
7
.f

b
I

GROWTH STIMULATION OF PULMONARY ADENOCARCINOMA
AND THEIR CELLS OF ORIGIN BY "CHEMOPREVENTIVE" AGENTS
THAT INCREASE INTRACELLULAR cAMP

A Dissertation
Presented for the
Doctor of Philosophy
Degree
The University of Tennessee, Knoxville

Hussein Abdulhadi Nasser Al-Wadei
December, 2004

Copyright© 2004 by Hussein Abdulhadi Nasser Al-Wadei
All rights reserved.

11

DEDICATION

First of all the author would like to thank almighty Allah (God); the
compassionate, the merciful, for all of the blessings that he gives. The author dedicates
this dissertation to the soul of his father, Abdul-Hadi Naser Al-Wadei, who devoted his
life to his children, who viewed his sons as the best sons in the world, who always
scarified and lived away instead of living close to his children, and grand and great
grandchildren; however, he always encouraged them to join in the vast world and to live
full lives. He asks Allah (God) to protect his father's soul and body from hell fire.
Furthermore, the author will keep his father beneficial advice in his mind for ever. He
also dedicates this dissertation to his mother Fatemah Yahya Al-Wadei, who at the last
moment still ignored to travel to the other world without seeing the picture of her son;
who the last thing she did in her very special life was to give her best wishes to her son,
daughter-in-law and grandchildren in the United States. This dissertation is also dedicated
to his brothers, Hameed, Dr. Khalid, Naser; and his sisters, Horea, and Aisha, for their
constant love and assistance, and for teaching him everything is possible. The author
presents his heartfelt thanks to all the members of his extended family, such as uncles
especially my Uncle Nasser bin Nasser Mofleh, who has encouraged me to finish my
higher education and always provide me with valuable life lessons, brothers and sisters
in-law. Loved ones in both families of the author also offered tremendous love and
encouragement, which helped him and his family to safely go through many hardships of

iii

the course. Living a fuller life and doing better things is only one way that the author can
reward these loved ones.
The author can not wrap up this section without expressing his most sincere
dedication to his sweetheart, Aisha Ghilan Abu-Farea, for her omnipresent love and a
lifetime of support and encouragement, and his wonderful sons, Mohammed, Yusof, and
Hussan; and his daughters, Al-Anood, Abeer, and Rahaf respectively. Their love, their
mighty power and their understanding attitude have been the utmost reliable support,
providing the best shelter in which the author can live. Their sacrifice to his academic
life has been priceless. The author also thanks all of his children for approving
continuation of his study leave, and in so doing, suspending their natural right to be cared
for by a father.

IV

ACKNOWLEDGEMENT

The author received various forms of assistance from many people in the course
of producing this dissertation. He is glad to use this opportunity to express his
indebtedness and respect to all of them. First and foremost to his major advisor, Dr.
Hildegard M. Schuller, for her special care, encouragement, unreserved professional
guidance and stipend support throughout the course of this study. Without her invaluable
concerns, and efforts, without her assistance, the author would have never had the
wonderful opportunity to learn, to share, and to experience the excellent environment of
the University of Tennessee, Knoxville, United States of America. The author sincerely
appreciates his major advisor's kindness and willingness to speak with him with or
without an appointment.
From the very first personal meeting with Dr. Schuller, the author was happily
impressed by her frank concerns not only about the research project but also the other
aspects of cancer rather than her area of interest. During service on the committee, Dr.
Schuller has fed the author with valuable food for thought, which reminded the author to
pay more attention to the economic impacts of the research project. Dr. Schuller's
guidance and suggestions have been invaluable during my work on this dissertation.
Thanks may not be enough to express the author's appreciations.
The author expresses his deep thanks to Dr. Potgieter, L.N.D, who has done much
to encourage and to help the author, before, during and surely after the course of this
study. Also, his service as a member of the author's committee is sincerely appreciated.
V

The author also expresses his appreciation to the rest of the members of his
committee, Dr. Michael D. Karlstad, Dr. Howard K. Plummer III for their time, academic
guidance and encouragement. The author was lucky to have many opportunities to work
closely with Dr. Plummer, from whom he learned both academic aspects and working
manner.
During the course of this study and dissertation research, Dr. Robert N. Moore,
Associate Dean of Graduate Programs, provided the author with special support, a variety
of life experiences and valuable lessons.
The author is very grateful to the entire academic, technical, and administrative
staff members and Ph.D. students of the Department of Comparative and Experimental
Medicine group. He really enjoyed a lovely working environment and social events with
them, which he can never forget. His special words of thanks go to Dr. Mourad Majidi,
and Essam Leag, for their help and valuable suggestions in trouble shooting in the
laboratory work. Thanks also to Maria CeKanova for her assistance in the laboratory.
Thanks to Debbie Hampstead, Diane Dodson, Colleen Ailor, Missy Hodge, Emily Dyke,
and Jamie Turner for their kindness and nice assistance. Thanks also to Jada Huskey for
her ready availability and willingness to offer comments and suggestions.
The author would like to express his many thanks to Minoo Askari and Kindra
Walker, whom from the beginning have shown their support and enthusiasm for assisting
in the laboratory. The author considers himself very lucky to join the wonderful
environment of the Department of Comparative and Experimental Medicine and the
University of Tennessee, for his study as well as his life. He gained confidence at work,
with friendly relationships with faculty professors, staff and graduate fellows. He highly
Vl

recognizes and sincerely appreciates the warm-hearted concerns and useful assistance
from many members of the Department of Comparative and Experimental Medicine.
Face after face, smile after smile, have been stored in the author's memory and surely
will never be forgotten.
The most determinant guarantee for the success of his study in the U.S. was the
scholarship stipend provided by Dr. Schuller's NCI grants at the Department of
Pathobiology, Comparative and Experimental Medicine at the College of Veterinary
Medicine, University of Tennessee, Knoxville. The author is indebted to this generous
grace and he will always remind himself that he has to do something better in the future
to show his great appreciation. This work was supported by grants # RO1 CA096128 and
RO 1 CA88809 with the National Cancer Institute (NCI).
During four years living and studying in the U.S. the author and his family
received a great deal of care, concern and assistance from many friends in Knoxville,
including Fawaz El-Salem and his Wife Lara and many others. Other friends around the
U.S.have been supportive, including Dr. Ahmed Rashdi in Oregon, Emad El-Gayyar and
Hamed Yusof in Mississippi, Abdullah Alsokatri at Yemen Embassy, Kareman Al
shareef, Khalid Al-Nageeb, Rasha and recently Dr. Yassin Al-Shaibani at Cultural office
at Yemen Embassy in Washington D.C., and many others.

Support from his native

country from his best friends, Dr. Abdul-Rahman Nassar, Dr. Saleh Al-Sharabi, Dr.
Ameen Al-Hemyari, Dr. Hasan Al-Ahadal, Dr. Manea Al-Hezami, Dr. Omar Al-Bakri,
Dr. Ali Albar, Dr. Abdulwali Al-Aghbari, Dr. Gameel Al-Maktari, Dr. Khalid Al
Maktari, Dr. Abdul-Wali Al-Aghbari, Dr. Ahmed Al-Molsy, Ali Ghilan Abu-Farea,
Abdul-Kareem Ghilan Abu-Farea, Saleh Ali Mofleh, Saleh Mohammed Mofleh, Hasan
Vll

A. Al-Rabal, and all of the author's best friends. Your warm care and concern offered to
me and my family is most appreciated and will not be forgotten.
The author would never dare to ignore the partial financial support from Sana'a
University, Yemen. As matter of fact, without these sources of support, the author's
dream of studying in U.S. would have never been realized.
The author's successful study and his wonderful family life in the U.S would not
have happened without the tremendous love, care and assistance from many, many
friends all over Yemen. Persistent emails and phone calls from them have been 'essential
nutrients' in the author and his family's daily menu. Through the courses of his study, the
author experienced more and reconfirmed these invaluable friendships.
Last but not least, the author highly recognized that the power he has, the wisdom
he owns, the love he can share with others and the way he goes in his life, all come from
his family heritage.
If I have omitted someone from this acknowledgment, it is purely unintentional.
The number of people I'm thinking about while writing this is very long indeed, and I
collectively thank you all even if your names were not mentioned.

vm

ABSTRACT

Lung cancer is the leading cause of cancer mortality for men and women in the
United States, with a high mortality rate and a five-year survival rate of less than
15%.Cancer ranks second as a cause of death for Americans after cardiovascular disease.
The American Cancer Society (ACS) reported 171,900 new cases of lung cancer for 2003
(ACS, 2003). Peripheral adenocarcinoma (PAC) of the lung has increased dramatically
over the last 20 years and is the leading histological type of lung cancer in smokers and
nonsmokers in industrialized countries, including the United States. Among the four
main histological lung caner types (small-cell carcinoma, squamous-cell carcinoma,
adenocarcinoma and large-cell carcinoma), adenocarcinoma that is derived from small
airway epithelia with features of Clara cells accounts for about 35-40% of all lung cancer
cases. Unlike other .. histological lung cancer types, adenocarcinoma also develops in a
significant number of non-smokers.
Smoking remains the greatest contributor to the development of lung cancer, with
90% of all lung cancer cases estimated to be smoking related. Cigarette smoke contains
about 4,000 toxic chemicals including the highly carcinogenic nitrosamine, 4(methylnitrosamino)-1- (3-pyridyl)-1-butanone (NNK). NNK is the most potent
carcinogen in laboratory animals and has therefore been implicated as a significant cause
of tobacco-associated cancers in human.
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Dietary and genetically determined factors appear to play an important role in
modulating individual susceptibility to smoking-associated cancer and are closely linked
to the chemoprevention approach.
Chemoprevention is defined as the use of naturally occurring or synthetic agents
to prevent, inhibit or reverse the process of carcinogenesis. This relatively new approach
of cancer prevention has precedence in other areas of medicine such as cardiovascular
diseases.
Earlier studies have shown the presence of a �-adrenergic/cAMP growth
regulating pathway in PAC. Therefore, �-adrenergic stimulants in various drugs that are
used for the treatment of chronic respiratory and cardiovascular diseases have been
proposed as potential risk factors for the development of PAC. Furthermore, little is
known about the downstream effectors of this pathway and their role in the regulation of
proliferation of PAC and their normal cells of origin.
Using assays for the assessment of cAMP production, PKA activity, MAPK
activation, CREB activation, and cell proliferation, we have identified a mitogenic
pathway, which activates cAMP in cell lines derived from human peripheral
adenocarcinomas that express features of Clara cells and their normal cells of origin,
small airway epithelial cells (SAEC).
�-carotene and a substance contained in green and black tea, theophylline are
widely believed to have cancer preventive effects. However, our current data show that
each of these agents increases cAMP/PKA activity, ERKl/2 and CREB resulting in a
significant growth stimulation of PAC and SAEC. Accordingly, and pending on the exact
level targeted by a given chemopreventive agents, such treatments will likely promote the
X

development of PAC. While some of these agents may inhibit the metabolic activation of
tobacco carcinogens, such as NNK, former smokers who start chemoprevention will not
benefit from such effects as they start chemopreventive treatment after discontinuation of
exposure to tobacco carcinogens. Currently, there is no agent that has been shown to be
effective in preventing lung cancer. Accordingly, the most effective prevention of lung
cancer is never to smoke and to avoid exposure to second hand smoke.
Our study findings suggest that the widely advertised cancer preventive agents
that currently are still tested by several laboratories as "chemopreventive" agents such as
�-carotene and a substance contained in green and black tea, theophylline are unsafe to be
used by smokers or by ex-smokers due to their tumor promoting effects via stimulation of
cAMP on initiated cells of Clara cell lineage.
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PART I:
Introduction

1

I. Introduction

Peripheral adenocarcinoma (PAC) of the lung has increased dramatically over the
last 20 years. PAC is today the leading histological type of lung cancer death in smokers
and non-smokers in both men and women of industrialized countries, with a high
mortality rate and five-year survival rate of less than 15% after diagnosis (1-4).
According to a recent report by the United States Surgeon General, lung cancer in women
has increased by 600% since the 1950s and has reached epidemic levels (5, 6). Since the
late 1980s, lung cancer in women has surpassed breast cancer as the leading cause of
cancer death (7). The American Cancer Society (ACS) reported 171,900 new cases of
lung cancer for 2003 and 173,770 new cases and 160,440 deaths are expected in the
United States in the year 2004 (8). Lung cancer ranks as a second cause of death after
cardiovascular disease (9).
The most important risk factor for lung cancer is cigarette smoking, which
accounts for 80-90% of all cases (10, 17). The only effective means of lung cancer
prevention is never to smoke or giving up smoking (11). Lung cancer is usually detected
at an advanced stage of development when metastasis and drug resistance have already
developed (12). The prognosis has not been improved by chemoprevention because ofthe
lack of an effective systemic treatment (13, 14). The incidence of lung cancer has slowly
decreased among men in developed countries, whereas it has increased in women (10).
However, lung cancer is the main cause of cancer death in both sexes, with an annual
mortality rate of91 % (15).
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Among the four main histological lung cancer types (small cell carcinoma,
squamous cell carcinoma (SQC), adenocarcinoma, and large cell carcinoma),
adenocarcinoma that is derived from small airway epithelium with feature of Clara cells
accounts for about 35-40% of all lung cancer cases ( 16). Small cell carcinoma and
squamous cell carcinoma are developing exclusively in smokers (3, 4) while PAC is
additionally found in a significant numbers of non-smokers (3). Moreover, PAC
frequently develops in patients under the age of 50 as opposed to other types of lung
cancer that are typically diagnosed in patients of age 60 and older ( 18).
An alarming increase in teenage smoking will without doubt, raise the lung cancer
epidemic even farther in the years to come (19). The development of effective treatments
that prevent the progression of precancerous lesions or early stage lung cancers into overt
cancers in smokers, who quit, are therefore urgently needed. Mouse models are widely
used in preclinical studies to test the efficacy of novel chemopreventive agents. Studies in
our laboratory have shown that the growth of human PAC cell lines of Clara cell lineage
(PACC) in vitro and of PACC induced in hamsters by the nicotine-derived nitrosamine,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) are regulated by beta-adrenergic
receptors through the activation of cAMP (20-23). These experiments also demonstrated
that the in vitro and in vivo growth of PACC is promoted by the beta-adrenergic agonist
epinephrine and by the cyclic nucleotide phosphodiesterase inhibitor theophylline (2023). These findings suggest an important role of beta-adrenergic receptors and their
downstream effector cyclic adenosine monophosphate (cAMP) in the growth regulation
of PACC. By contrast, studies of PAC derived from alveolar type II cells in mice and in
human squamous cell carcinoma (SQC) have identified signaling via the epidermal
3

growth factor receptor (EGFr) pathway and a PKC-mediated pathway as an important
growth regulating events (24-30).
The major concern with respect to preclinical lung cancer prevention is the fact
that, these pathways appear to be antagonistic at the level of cAMP/PKA. While agents
that activate or increase intracellular cAMP may inhibit the EGF or PKC pathways via
inhibiting Raf-1, these may promote �-adrenergic, cAMP- mediated growth regulating
pathways. Accordingly, chemopreventive agents that interact with �-adrenergic/cAMP
signaling pathway treatment may prevent the development of alveolar type II cell
carcinoma or squamous cell carcinoma while promoting the development of PACC.
In the 1990s, a comprehensive international chemoprevention trial with �
carotene and retinoids was conducted in smokers and ex-smokers (carotene and retinoid
efficacy trials, CARET). This trial was based on preclinical studies that had identified
significant

chemopreventive

effects

of �-carotene

and

retinoids

on

rodent

tracheobronchial SQC (31). Five years into the trial, this study had to be discontinued due
to a 46% increase in lung cancer mortality and a 26% increase in cardiovascular mortality
in groups receiving beta-carotene and retinyl palmitate (14, 32-36).
Another popular "chemopreventive" agent, green tea, has shown mixed results in
epidemiological studies with some reports demonstrating a reduction in lung cancer risk
(37-42, 44), while others reported no effect or even promoting effects on lung cancer (40,
43, 45-49). Green tea contains significant amounts of theophylline which, due to its
inhibiting effects on phosphodiesterase, increases intracellular cAMP (34). Because
PACC and cardiovascular function are both under �-adrenergic control and both diseases
were presented in the caret trial (20-23), the hypothesis of the current project is that �4

carotene and theophylline (which is contained in tea and asthma medications) promote
the growth of PACC via their documented ability to increase intracellular cAMP (33, 3436).
Using assays for the assessment of cAMP production, PKA activity, MAPK
activation, CREB activation and cell proliferation. This proj ect has characterized cAMP,
PKA, CREB and ERK 1 /2 as components of a mitogenic signal transduction pathway in
cell lines derived from human PACC and their normal cells of origin, small airway
epithelial cells (SAEC). The selective nature of this growth-promoting pathway on PACC
and SAECs was confirmed by studies in a cell line derived from human large airway
epithelial cells (BEAS-2B). Contrary to PACC and SAECs, these cells responded with a
growth inhibition to �-carotene.

5

Working hypothesis

The central hypothesis of this project is that the pro-vitamin A, P-carotene and a
substance contained in green and black tea such as theophylline, promote the growth of
the human PACC cell line NCI-H322 and their normal cells of origin, SAEC. Data
generated by this project supported the hypothesis and showed that both of these
"chemopreventive" agents stimulated cell grown in both cell systems, an effect mediated
by activation of cAMP,PKA,CREB and ERKl /2.

Specific aims

1 . To test the hypothesis that P-carotene stimulates the growth of pulmonary
adenocarcinoma (PAC) cells and their normal cells of origin, small airway
epithelial cells (SAEC), and to identify signal transduction components involved
in this effect.

2. To test the hypothesis that theophylline stimulates the growth of pulmonary
adenocarcinoma (PAC) cells and their normal cells of origin, small airway
epithelial cells (SAEC), and to identify signal transduction components involved
in this effect.
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Literature Review
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I. Lung cancer overview

At the beginning of the 20th century, lung cancer was considered a rare disease ( 1 ,
2 , 27). However, since then the incidence of lung cancer has dramatically increased to
become one of the most common malignancies and the leading cause of cancer death
with a high mortality rate and five-year survival rates of less than 1 5% in developed
countries (3 , 4). New lung cancer cases diagnosed throughout the world in 2002 were
estimated to be approximately 1 .2 million and more than 90% of these cases are expected
to die from this disease (5, 6).
Approximately 1 ,334, 1 00 new cases of cancer were diagnosed and approximately
556,500 died from cancer in the United States in the year of 2003 (7). Lung cancer was
the second leading type among new cancer cases ( 1 7 1 ,900; 1 3% of the total) and the first
in cancer death (1 57,200; 28% of the total) in the United States (7). For the year 2004,
1 73,770 new cases of lung cancer and 1 60,440 deaths are expected in the United States
(8, 9). Unfortunately, the National Cancer Institute' s stated goal of a 50% reduction in
overall cancer mortality by the year 2000 has not been met and the death rates from some
of the common cancers continue to rise ( 1 0). In addition, the total annual direct and
indirect costs of cancer care in the United States have been estimated at more than $96
billion (1 1). The death rate for lung cancer exceeded the combined total for breast,
prostate, and colon cancer in developed countries (7, 1 2, 1 3). It is the most frequently
diagnosed cancer type and the most common cause of cancer deaths in males and females
in the world. This trend is also expected to continue for many years (14). The
convergence of lung cancer death rates among men and women born after 1 960s support
13

the idea that males and females may be equally susceptible to developing lung cancer
from a given amount of cigarette smoking, years of smoking, earlier age of onset, degree
of inhalation, tar and nicotine content, and use of unfiltered cigarettes. Lung cancer in
women has increased by 600 % since 1950 and has reached epidemic levels (7, 4, 15), an
effect likely associated with the simultaneous observed increase of women who smoke.
Lung cancer has surpassed breast cancer as leading cause of cancer death in women since
the late 1980s (13). The birth-cohort pattern of lung cancer mortality after 1950 appears
to reflect the early impact of teenage cigarette smoking on lung cancer risk on people
under the age of 45 years (16). Before that, lung cancer was a rare disease in individuals
under 40 years of age. Lung cancer is most frequently diagnosed in patients 50-75 years
of age, and the incidence is higher among patients in 65-75 years old than in 55-64 years
old group (17). In addition to that, individuals who stop smoking after the age of 50 may
retain a substantial risk for lung cancer life-long (18, 19).
Unfortunately, 1 ung cancer is usually diagnosed after the development of
metastasis and drug resistance (20). Despite improvement in the diagnosis and treatment,
the mortality rate remains higher than 95% within one year of diagnosis (21, 22).
A large number of risk factors have been identified for the development of lung
cancer, such as cigarette smoking, airflow obstruction, and exposure to asbestos, radon,
arsenic, ionizing radiation, haloethers, polycyclic aromatic hydrocarbons, and nickel (23).
Cigarette smoking is the single most extensively documented risk factor for lung cancer,
accounting for - 90% of cases in men and 70-85% of cases in women (23-28, 20).
Genetic risk factors contribute to an individual's susceptibility to lung cancer, which is
illustrated by the fact that more than 16% of long-term smokers will develop lung cancer
14

(29). So far, a recent study reported a relationship between environmental tobacco smoke
exposure and increased lung cancer risk among nonsmoking women with a common
genetic deficiency in glutathione S-transferase Ml (GSTMl ) enzymatic activity because
of a genetic polymorphism in the GSTMl gene (30). Life style factors such as diet are
also thought to be important in the modulation of lung cancer risk (29).
The World Health Organization (WHO) distinguishes two major lung cancer
families: non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC).
Among the family of NSCLC, adenocarcinoma (3 5-40%), squamous cell carcinoma (2530%) and large cell carcinoma ( 1 0-1 5%) are recognized. Small cell lung cancer often
responds to chemotherapy but then relapses while NSCLC is usually non-responsive (3 1 ).
Pulmonary adenocarcinoma tends to grow very fast (32). The tumor grows along
the alveoli and the tumor cells are bigger than normal cells and tend to cluster together
and exhibit epithelial cells (32). It has been suggested that pulmonary adenocarcinoma
PAC be reclassified into five cells types: bronchial surface epithelial cell type, with little
or no mucus, goblet cell type, Clara cell type, type II alveolar epithelial cell type, and
bronchial gland cell type (33). On the other hand, it has been suggested to classify PAC
into: hobnail cell type, columnar/cubical cell type, polygonal cell type, and goblet cell
type (34). Also in 1 999, the WHO classified PAC into five subtypes; acinar, papillary,
bronchioalveolar carcinoma, solid adenocarcinoma with mucin, and adenocarcinoma of
mixed cell type (35).
PAC has risen dramatically during the last three decades from a very rare type of
lung cancer to be the leading type of lung cancer today (2, 28). PAC accounts for about
60% of all lung cancer cases (2, 28, 36, 3 8) and is particularly prominent in women and
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African Americans (37). In the near future, this trend of PAC is expected to cover many
geographical regions ( 1 ). It has been estimated that the mortality from adenocarcinoma
will increase world-wide in contrast to squamous cell carcinoma and small-cell
carcinoma for which a decrease is expected.
PAC is the only histological lung cancer type that develops in a significant
number of non-smoking individuals implying, that additional factors other than smoking
contribute to the continued rise of this cancer type. Studies by Park et al. 1995 (39) and
Schuller et al. 1999 (40) showed that the growth of PAC of Clara cell linage in vitro and
in an animal model is under beta-adrenergic control and that the tobacco-specific
carcinogen NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone] is the most potent
stimulator of this proliferative pathway. In addition to that, the chronic treatment of
existing respiratory diseases such as asthma and chronic obstructive pulmonary disease
(COPD) by �-adrenergic stimulators might play a significant role in the PAC epidemic.
For instance, COPD is one of the most common respiratory conditions of adults in the
developed world, which encompasses both chronic bronchitis and emphysema (41 ). In
fact, patients with COPD should be monitored carefully for lung cancer (42).
An alarming increase among teenage smoking will, without doubt, increase the
lung epidemic even farther in the years to come (16). The developments of effective
treatments that prevent progression of precancerous lesions, or early stage lung cancers,
into overt cancer in smokers, who quit, are therefore urgently needed. Mouse models are
widely used in preclinical studies to test the efficacy of novel chemopreventive agents.
On the other hand, studies ofClara cell-derived PAC induced by NNK in hamsters have
shown that these lung tumors express �-1 and �-2 adrenergic receptors and that their
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growth is promoted by the �-adrenergic agonist epinephrine and by the cyclic nucleotide
phosphodiesterace inhibitor theophylline (43, 44, 45). Those findings suggest an
important role of �-adrenergic receptors and their downstream effector cyclic adenosine
monophosphate (cAMP) in the growth regulation of lung tumors of Clara cell lineage. In
contrast to the hamster, NNK-induced PAC in mice is of alveolar type II cell lineage and
their growth is inhibited by agents that stimulate cAMP (46-51, 20). Chemopreventive
agents that stimulate �-adrenergic/cAMP signaling may therefore prevent the
development of lung cancer in mice while promoting the development of PACC in
hamster and man. In support of this hypothesis we have recently shown that green tea
which contains the phosphodiesterase inhibitor theophylline as well as injections with
theophylline have strong growth promoting effects on experimentally induced PACC in
hamsters (45).

II. Chemoprevention (CP)

Currently, in the United States and Canada alone, there are approximately 50
million former smokers and 50 million current smokers (52). As a result of this large
population of people at risk, an alternative cancer control method such as
chemoprevention needs to be developed to reduce lung cancer mortality, especially for
smokers who have followed medical advice to give up smoking. Michael Sporn was the
first researcher who described chemoprevention (53) in 1976 and defined it as "the use of
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specific natural or synthetic chemical agents to reverse, suppress or prevent carcinogenic
progression to invasive cancer." Proof of principle studies by Ki Hong and co-workers
(54-56) showed that chemoprevention could prevent cancer in the upper aerodigestive
tract. Around 2000 natural and synthetic agents have been shown in experimental
systems to have chemopreventive activity. Vitamin A was first noted to be an essential
nutrient in 1913, while in 1925 vitamin A deficiency was reported to be associated with
changes in epithelial histology. Since that time, vitamin A deficiency has been associated
with bronchial metaplasia and an increased incidence of cancer (57-61). The pro-vitamin
A, �-carotene, is also one of the most widely studied chemopreventive agents that has
been tested in clinical trials (65). Chemoprevention trials for lung cancer have been
carried out in phase III clinical trials for over a decade with mostly negative results ( 6266). Although, a combination of beta-carotene and vitamin A supplement for an average
of four years had no benefit and may have had an adverse effect on the incidence of lung
cancer and on the risk of death from lung cancer, cardiovascular disease, and any cause in
smokers and workers exposed to asbestos (62).
Chemopreventive agents (CPA) may affect cellular proliferation, differentiation,
apoptosis and tumor angiogenesis (67). In primary prevention trials, three large studies
demonstrated that neither a-tocopherol nor beta-carotene had preventive effects on lung
cancer (68, 62, 63). In the 1990s, a comprehensive international chemoprevention trial
was conducted in which smokers and ex-smokers were treated with �-carotene or
retinoid. However, the �-Carotene and Retinol Efficacy Trial (CARET) and Alpha
Tocopherol, �-Carotene {ATBC), showed that agents which effectively inhibit lung
cancer growth in a preclinical model of hamster tracheo-bronchial organ cultures had the
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opposite effect on human lung cancer. Five years into the trials, this study had to be
discontinued due to a 46% increase in lung cancer mortality and a 26% increase in
cardiovascular mortality in the groups receiving �-carotene and retinyl palmitate (62, 66).
As cardiovascular function as well as the growth regulation of PAC are under beta
adrenergic control, we hypothesized that �-carotene caused the dramatic increase of both
diseases in this trial because it increases intracellular cAMP by inhibition of the enzyme
phosphodiesterase (69). We further hypothesized that beta-carotene would have selective
strong promoting effects on the growth of human pulmonary adenocarcinoma cells of
Clara cell phenotype (NCI-H322) and their normal cell of origin (SAEC) via its
stimulatory effects on cAMP. We have also included theophylline in our experiments
because it has the potential to increase intracellular cAMP.
Beta-carotene is a member of the carotenoid family that consists of over 600
compounds found predominantly in fruits and vegetables and is converted by the
mammalian organism to vitamin A. This molecule has been reported to have a number of
actions, including important antioxidant activity due to its inhibition of radical initiated
peroxidation in vitro (70-73). Original epidemiologic data showed a positive association
between f3-carotene deficiency in the diet and increased risk of lung cancer (58, 59, 60, 72
-75). On the other hand, clinical trials involving �-carotene supplementation revealed
unfavorable effects (62-65, 56, 68, 70). Among the possible explanations for this effect
inhibition of absorption of other nutrients by large doses of �-carotene and the
autocatalytic pro-oxidant activity of �-carotene under high oxygen tension such as that
occurring in the lungs of smokers were discussed (74-76). The ability of beta-carotene to
increase intracellular accumulation of cAMP by inhibiting phosphodiesterase ( 69) has not
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been considered to date as a cause for the observed lung cancer promoting effects. Also,
it has been suggested that �-carotene increases mortality of lung cancer and
cardiovascular diseases (73). However, chemoprevention of lung cancer is proving
difficult and frustrating (77). In general, lung cancer chemoprevention trials have been
disappointing. Several large-scale chemoprevention trials have been performed, including
the European Organization for Research and Treatment of Cancer Head and Neck and
Lung Cancer Cooperation Groups (EUROSCAN) Trials, the Physician Health Study, the
Alpha-Tocopherol and Beta-Carotene trial (ATBC, CARET), which involved thousands
of active smokers followed up for over 1 0 years. Unfortunately, none of those studies
have yielded favorable results.
Green Tea (GT) was discovered in the year of 2737 BC by the Chinese emperor
Sheng Nung. The traditional use of tea began in China about 4700 years ago and it was
often used as medicine. In the 8th century, tea was introduced in Japan and in Europe, and
then very rapidly became an important commercial product throughout the world. (78).
Tea is the most ancient and widely consumed beverage in the world next to water,
made from leaves of the Camellia sinensis species of the theaceae family (79). Fresh tea
leaves are rich in flavanol monomers of the polyphenol family known as catechins. The
predominant catechins found in tea are epicatechin (EC), epicatechin gallate (ECG),
epigallocatechin (EGC), and epigallocatechin-3-gallate (EGCG). EGCG is the most
potent and widely used catechin in tea (80). While some sources additionally contain
gallo catechin (GC) all of the catechins are contained in green tea extract GTE that is
widely used as a dietary supplement. Green tea constituents have been characterized as
antioxidants that scavenge free radicals to protect normal cells. The antioxidant effect is
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directly related to the combination of aromatic rings and hydroxyl groups that make up
the structure and also a result of binding and neutralizing of free radicals by the hydroxyl
groups (8 1 ). However, results of epidemiological studies on tea and cancer have been
inconsistent; some show consumption of tea is protective, whereas others show it either
has no relationship with cancer or even increases the risk of certain cancers (82).
Lung cancer studies have shown an inverse effect with Okinawan tea, yet a
tentatively increased risk was shown in another study (83, 84). Although human studies
have their limitations, the research has warranted a further look into the effects of green
tea and cancer (83). However, early studies focused on the effects of polyphenols and
catechins in tea on cancer development, while recent studies have identified anti
mutagenic, anti-proliferative, and anti-neoplastic effects of all tea fractions (85),
suggesting that non-catechin components of tea contribute to the cancer modulating
effects of tea. Theophylline which is also contained in tea has been given little attention
by cancer researchers. This agent is a widely documented inhibitor of phosphodiesterase
(85-88, 89) and increases intracellular cAMP via this mechanism. In the current projects
experiments on NCI-H322 and SAEC have been performed to test the hypothesis that
theophylline which is the main component of green tea, promotes growth-regulating
signal transduction.
The principal current use of theophylline began in the early 1 970s with reports
demonstrating its efficacy as preventive medicine for chronic asthma (90) and by 1 980,
theopyhlline had become a leading medication for asthma because of its bronchodilating
effects (9 1 ). Theophylline in fact, has immunomodulatory (92), anti-inflammatory (93,
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94, 42), and bronchoprotective effects that potentially contribute to its efficacy as a
prophylactic antiasthma drug (95-97).

III. Growth-Regulating Signaling Pathways Expressed in Lung
Epithelia and Lung Cancer

The epidermal growth factor receptor (EGFR)
Generally, a signal is transmitted from the cell membrane to the nucleus through
interaction of proteins, and conversion of those proteins from inactive to active status.
This begins with the interaction of signals with the membrane receptors. This
extracellular signal may include growth factors hormones, neurotransmitters,
extracellular matrix, and stress signals. This interaction activates the receptor, which then
catalyzes a series of reactions beginning with the activation of a secondary protein, often
through cofactors such as ATP, GTP, cAMP, or cations. This protein often catalyzes the
activation of the third protein, and this pattern continues in a cascade of reaction, usually
involving cytoskeleton proteins like beta-catenin and APC, adapter proteins, kinases and
phosphatases. The kinases can be either receptor, like the EGF receptor, or non receptor,
like Src and Jak. This cascade culminates in the activation or deactivation of transcription
factors, like c-myc, or other factors, and translocalization of these factors into the nucleus
(89, 1 01, 103-106).
Cell growth is regulated by several growth factors by activating intracellular
signaling pathways after binding to high affinity tyrosine kinase receptors on the cell
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surface. Among these, the mitogenic activated protein kinase (MAPK) pathway plays an
important role in the transduction of mitogenic signals initiated by growth factors acting
on a variety of cell surface receptors. MAP kinases are regulated through many protein
phosphorylation cascades (89, 1 01 , 1 03-1 06).
Several stimulatory growth factors are found in lung cancers including, epidermal
growth factor (EGFR), transforming growth factor alpha (TGFa), insulin growth factor1 /2 (IGF-1 /2), platelet derived growth factor-A/B (PDGF-A/B), fibroblast growth factor
(FGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor, (HGF), and
mammary derived growth factor- I (MDGF- 1 ) (98, 99). The epidermal growth factor
receptor (EGFR) is a 170 KDa transmembrane receptor with tyrosine kinase activity,
which has several ligands including EGF, amphiregulin (AR) and TGFa (98). EGF and
EGFR are frequently over-expressed in lung cancers ( 117, 1 1 8).
The EGFR signaling pathway demonstrates remarkable flexibility in mediating a
host of signaling pathways that regulate various physiological and pathological processes.
The EGFR belongs to the receptor tyrosine kinases (RTKs) family. RTKs have an
intrinsic enzymatic activity in the cytoplasmic region that is directed against the receptor
and downstream signaling molecules (100). The RTKs are involved in a range of cellular
physiology including fertilization, proliferation, cell migration and apoptosis.
Furthermore, they play an important role in cancer development (101).
The EGFR is expressed in many cell types as well as regulates many cell
functions (102, 1 03), and it has four closely related receptors called the EGFR family
(erbB l ), erbB2 (HER2), erbB3 (HER3), and erbB4 (HER4).

23

The Ras-mediated mitogen activated protein kinase (MAPK) cascade is one of the
best characterized signaling pathways initiated by EGFR activation. The Ras- mediated
EGFR-MAPK cascade is initiated when the growth factor Grb- 2 associated SOS (Ras
guanine nucleotide exchange factor) is recruited to phosphotyrosine residues of activated
EGFR. This association allows the exchange of GDP (inactive form of G-protein) to
GTP, which is the active form of G-protein. This is followed by membrane recruitment
and activation of the serine/threonine kinase Raf (MAPK kinase kinase), which in turn
phosphorylates and activates MEK (MAPK kinase). The dual-specific MEK
phosphorylates and activates the serin/ threonine mitogen activated protein kinases
(MAPKs) ( 1 04). There is increasing evidence that MAP kinase can be activated by a
variety of signals, including growth factors ( 1 05), phorbol esters ( 1 06) and calcium ion
(Ca2l ( 1 07).
In summary, the epidermal growth factor (EGF) pathway is found in many cancer
cells. In this cascade, EGF binds to its receptor (EGFR) leading to the dimerization of the
receptor. This leads to autophosphorylation of the receptor tyrosines, and recruitment of
proteins to the receptors, which bind to the receptor via their SH2 domains. One such
protein is Grb2-SOS. In tum, this protein activates Ras through conversion of GDP to
GTP. Ras then activates Raf. Raf activates MEK which activates MAPK (ERK). MAPK
activates factors such as SRF, ATF, c-fos, c-Jun, c-myc leading to gene expression and
cell proliferation ( 1 04, 1 08, 1 09).
Besides the classical Ras-mediated kinase cascade, various signaling molecules
could also undergo phosphorylation and activation upon binding to the phosphotyrosine
residues on activated EGFR. Activated Phospholipase C (PLC) hydrolyses membrane
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bound phosphatidylinositol (PI) yielding diacylglycerol (DAG) and inositol phosphates
( 1 1 0). Inositol phosphate regulates intracellular calcium, which together with DAG,
activates protein kinase C (PKC). PKC causes potent activation of ERK through the
direct phosphorylation and activation of Raf- 1 ( 1 1 1 , 1 1 2).
Phosphatidylinositol 3-kinase (Pl 3K) binds to phosphorylated tyrosine residues of
receptor tyrosine kinases (RTKs) ( 1 1 3). Phosphorylated inositol phospholipids
(Phosphatidylinositols) are required for the membrane localization of phosphoinositide
dependent kinase (PDK). PDK phosphorylates and activates protein kinase B (Akt),
which is involved in cell proliferation and inhibition of apoptosis (1 1 4). Recently
Akt/PKB was identified as a promoter of cancer cell invasion through increased motility
and metalloproteinase production (1 1 4). The requirement of P1 3K for the induction of
DNA synthesis in cells was demonstrated by Roche et al. 1 994 ( 1 1 5). Among the proteins
that become phosphorylated and activated by EGFR is the Janus kinase 1 (JAK 1 ) and
STAT to the nucleus for gene activation ( 1 1 6, 1 1 7).

The epidermal growth factor receptor and lung cancer
An autocrine growth loop is present when both receptor and its ligand are co
expressed in a cell with self-regulated proliferation ( 1 1 8). EGFR has been implicated as a
promoter of proliferation and progression of malignant cells via various autocrine growth
pathways that have been associated with the pathogenesis of many cancers (1 1 9).
Several studies have shown that EGFR plays a major role in the autocrine growth
of human non-small cell lung cancer (NSCLC) ( 1 20). The family of NSCLC consists of
adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and carcinoid (3 1 ).
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Expression and overexpression of EGFR was found in a greater proportion of squamous
and adenocarcinomas than in large cell or small cell carcinoma (120, 121). The co
expression of transforming growth factor-a. (TGF-a.) and the EGFR exists in many lung
cancer cell lines particularly in NSCLC (120, 50). TGF-a is the main and most important
autocrine ligand in NSCLC tumor formation. Moreover, activation of point mutations of
the Ras gene resulting in constitutively active mitogenic signals were observed in about
30% of NSCLCs (122, 123, 124).
Over-expression of EGFR is associated with reduced survival (121, 125, 126),
metastasis (127), and resistance to chemotherapy (126-128). In lung cancer, many
chemotherapeutic approaches have targeted the EGFR signaling pathway with
encouraging preclinical results (131, 132).

Signaling through G-Protein receptors
G protein-coupled receptors (GPCRs) are among the largest family of cell surface
receptors. They mediate signaling from a number of stimuli and ligands including peptide
and glycoprotein hormones, neurotransmitters, phospholipids and photons. These
receptors consist of an extracellular ligand binding domain, a seven transmembrane
domain, and heterotrimeric G-proteins (133, 134). The heterotrimeric G-proteins consist
of a, �' y subunits, which dissociate into active Ga-GTP and G�1-subunits after interaction
with ligand-bound receptor. However, there are numerous Ga-proteins, the main classes
of which are Gas , which activate adenylyl cyclase; the Gai , which inhibit adenylyl
cyclase; and Gaq which activate phospholipase C. Beside the Ga subunits, the G�-subunit
is also involved in regulating various effectors, including adenylyl cyclase, phospholipase
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C and A2 isoforms, serine threonine kinases, and protein kinase C ( 1 34, 1 35). When an
agonist binds to GPCRs, the bound GDP exchanges to GTP on the G-proteins leading to
the dissociation of G-protein into active Ga-GTP and Gpy subunits. Once the agonist
leaves the receptor, the subunits associate to each other again to form inactive form of G
protein (GDP) bound state ( 1 36- 1 3 8).
From events occurring at the cell membrane to make changes in gene
transcription, the cyclic AMP (cAMP)-dependent signaling pathway is a classic signaling
pathway that has been well characterized. Once ligand (hormones, neurotransmitters,
growth factors) bind to the specific receptors located in the plasma membranes, an
allosteric change occurs, allowing it to bind to the G-protein. The G-protein becomes
active and GTP binds to G-protein and GDP (inactive form of G-protein) will be
released. Now the G-protein can move and transfer a message from the receptor to the
catalytic subunit. The Gs protein then stimulates the activation of the enzyme adenylyl
cyclase, which converts ATP via hydrolyzation to cAMP. cAMP acts as a second
messenger to activate protein kinases which will phosphorylate other proteins such as
protein kinase A(PKA). Activation of PK.A results in the downstream activation of either
CREB or Erkl/2 and finally causes cellular response such as proliferation ( 1 39, 89).

p -adrenergic signaling and cancer
Beta-adrenergic receptors are members of the super family of seven
transmembrane G-protein coupled receptors encoded by a gene on chromosome 5 (1 40).
Beta-adrenergic receptors are classified into � 1 -,
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�2 -,

and �3-receptors ( 1 40, 1 4 1 ). In the

lungs, P 1 - and P2 receptors are widely distributed in epithelia, smooth muscle cells, and
endothelial cells (142, 143). p3-receptors have not been identified in lung tissues but are
abundant in adipose tissues. The functions of P-adrenergic receptors in �ndothelia,
bronchial smooth muscle cells, vascular smooth muscle cells, cardiac muscle, and
pulmonary macrophages has been well characterized. It is well established that beta
adrenergic signal transduction pathway plays a key role in cardiovascular disease and
asthma (144). It has also been shown that beta-adrenergic receptors regulate secretion of
alveolar type II cells, bronchiolar Clara cells and Mucociliary clearance (142, 143).
Elevation of cAMP influences cell physiology, including proliferation, survival,
and differentiation, either stimulating or inhibiting the response depending on cell type
and context. Conflicting effects reported for cAMP might result from differences in cell
types, concentration, and localization of the cAMP dependent protein kinase (145). There
are 9 isoforms of adenylyl cyclase enzyme and the tissue specific expression of the
specific isoforms determines the relative amount of cAMP in response to stimuli (89).
Moreover, the large number of possible combination of different G-protein subunits and
effector molecules allows cells to respond in different ways (146). Phosphodiestrase
degrades cAMP to 5 ' -adenosine monophosphate (5 ' -AMP) terminating the cAMP
mediated effect of hormone stimulation.
Cyclic AMP activates protein kinase A (PKA) which phosphorylates numerous
proteins, with subsequent modulation of different cellular functions, including gene
transcription. Gene transcription is mediated through the PKA-mediated activation of
cAMP-responsive transcription factors including cAMP response element binding protein
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(CREB), cAMP response element modulator (CREM), and activating transcription
factor- I (ATF- 1 ) (89).
The growth of some types of cancer is stimulated by �-adrenergic signaling. This
signaling pathway enhances the growth of human lung adenocarcinoma cell lines (3 9,
43), pancreas (1 47) or breast ( 1 48). Park et al, 1 995 (39) initially demonstrated the
mitogenic role of �-adrenergic signal transduction in human PAC of the Clara cell
phenotype. This work showed the importance of �-adrenergic stimulators/cAMP in the
proliferation of human

cancer cell lines derived from peripheral pulmonary

adenocarcinoma with features of Clara cells (NCI-H322) and their normal cell of origin
immortalized small airway epithelium cells.
Finally, current data imply that PAC of Clara cell phenotype and small airway
epithelia cells with characteristics of Clara cells respond to elevated cAMP levels in the
same manner. This is likely to have important clinical and epidemiological implications
since beta-adrenergic stimulators are active ingredients of drug formulations that are
widely used in the management of chronic respiratory diseases and dietary supplements
for weight control.
Figure 1 1 shows that beta-adrenergic receptors on pulmonary epithelial cells
activates GTP-binding proteins (G-proteins) coupled to receptor signaling, resulting in
the activation of adenylyl cyclase and cyclic AMP (cAMP), followed by activation of
protein kinase A (PKA) depending on the cell type, PKA can activate the transcription
factors cAMP response element binding protein (CREB), cAMP response element
modulator (CREM), activating transcription factor- I (ATF- 1), activator protein 1 (APl)
1

See all figures and figure legends in Appendix.
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or nuclear factor KB (NF- KB) which all regulate cell proliferation. Alternatively, PK.A
can activate the small G-protein RAP-1, leading to the activation of serine/threonine
kinase B-RAF, followed by activation of the mitogen-activated protein kinase (MAPK)
cascade and transcriptional activation of proliferation. PK.A can also activate
phospholipase-A 2 (PLA2) to release arachidonic acid (AA) from cell membrane
phospholipids. AA itself, as well as its metabolites such as prostaglandins and
leukotrienes, can also activate.
In Figure 2 the flow-chart represents a simplified version of beta-adrenergic
signaling in NCI-H3 22 and SAEC cells that has been focus of this proj ect. OTP-binding
proteins (G-proteins) coupled to receptor signaling, results in the activation of adenylyl
cyclase and cyclic AMP (cAMP), followed by activation of protein kinase A (PK.A). In
our proj ect, we hypothesized that PK.A can activate the transcription factor cAMP
response element binding protein (CREB). Alternatively, PK.A can activate the small G
protein RAP- 1, leading to the activation of serine/threonine kinase B-RAF, followed by
activation of the mitogen-activated protein kinase (MAPK) cascade, all of which may
lead to the activation of human cancer cell lines derived from peripheral adenocarcinoma
with features of Clara cells (NCI-H3 22) and their normal cells of origin (SAEC) and
transcriptional activation of proliferation. Also, depending on cell type, ERK 1/2 may
activate CREB or CREB may activate ERK.1/2.
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Figure 1 . cAMP-dependent signal transduction in response to �-adrenergic receptor
stimulation. Binding of agonists to the receptor will activate the enzyme adenylyl cyclase,
leading to the activation of the second messenger cAMP which in turn phosphorylates
other downstream proteins such as its associated protein kinase A (PKA). In turn, PKA
may phosphorylate the transcription factors CREB, CREM, ATF- 1 , or NF-kB, or
activation of PK.A may phosphorylate the MAPK cascade through the activation of Rap-I
and b-Raf or it may activate Phospholipase A2 which then leads to release of AA.
However, the activation of the transcription factors in all three different ways will cause
cellular response such as cell proliferation.
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Figure 2. Flow-chart represents a simplified version of �-adrenergic signaling in NCI
H322 and SAEC cells that has been focus of this project. cAMP-mediated signal
transduction pathway in response to �-adrenergic receptor stimulation. Once stimuli bind
to the receptor in the cell membrane, the enzyme adeny ly cyclase will be activated via
ATP hydrolyze, which then will activate the second messenger cAMP. cAMP will
activate protein kinase A (PKA), which in turn will activate either CREB or Erkl /2
which either one will finally causes cell proliferation.
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Introduction

Lung cancer is the leading cause of cancer deaths in industrialized countries { l -3).
Among the four major types of lung cancer recognized by the WHO classification
(adenocarcinoma, small cell carcinoma, squamous cell carcinoma, large cell carcinoma)
pulmonary adenocarcinoma (PAC) predominates today, accounting for about 60% of all
lung cancer cases (2, 4, 5). Smoking is a well documented risk factor for all types of lung
cancer (6, 7) while a high fat diet constitutes an additional risk factor for PAC (8- 1 0).
Human PAC may be derived from bronchiolar Clara cells or from alveolar type II cells.
Immunohistochemistry is primarily used to identify cell lineage of this cancer type by
using antibodies to the Clara cell-specific CC 1 0 protein and the alveolar type II cell
specific surfactant. Using this technique, PAC of Clara cell lineage has been reported to
account for about 50% of PAC cases (1 1 ). By contrast, electron microscopic
investigations have identified 90% of PAC as being derived from Clara cells ( 1 2).
Recent reports have shown that exposure to cigarette smoke or the tobacco-specific
carcinogenic nitrosamine 4 (methylnitrosamino)-1 -(3-pyridyl)-1 -butanone (NNK) down
regulate the expression of the Clara cell-specific CC l 0 protein in human and animal
lungs (1 3). These findings suggest that identification of PAC cell lineage by
immunohistochemistry

may

result

in

significant

numbers

of false

negative

immunoreactions to the CC 1 0 antibody because of down-regulated CC 1 0 in smokers.
Accordingly, a higher proportion of PACs are likely of Clara cell lineage than is
generally accepted in the literature.
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Studies in our laboratory have shown that the in vitro growth of human lung
cancer cell lines derive from PAC of Clara cell lineage are regulated by P-adrenergic
receptors and that the tobacco-specific carcinogenic nitrosamine 4-(methylnitrosamino)
(3-pyridyl)- 1 butanone (NNK) acts as an agonist for this receptor family (14). NNK as
well as a stimulator of the classic downstream effector of P-adrenergic receptors, cAMP,
significantly stimulated DNA synthesis of these cells in vitro (14, 1 5). In support of these
data, studies in a hamster model of NNK-induced Clara cell-derived PAC have shown
that P-adrenergic agonists ( 1 6) and the phospodiesterase inhibitor theophylline ( 1 7) ,
which causes intracellular accumulation of cAMP, each significantly promoted the
development of this cancer type .
A multinational chemoprevention trial with P-carotene and retinoids (P-carotene
and retinoid efficacy "CARET" trial) was conducted in the 1 990s in populations at risk
for the development of lung cancer because of previous or current exposure to smoking
or asbestos ( 1 8, 1 9). This trial was based on preclinical studies that had shown in vivo
and in vitro inhibition of chemically induced carcinogenesis in the upper airways of
hamsters by the pro-vitamin P-carotene or by synthetic vitamin A analogues of the
retinoid family (20-24). In addition, a strong promotion of diethylnitrosamine-induced
tracheobronchial carcinoma by vitamin A-deficiency was reported in hamsters (25). The
trial had to be discontinued after 5 years due to a 28% increase in lung cancer incidence
and mortality (46%) and a 26% increase in cardiovascular mortality ( 1 9). Conclusive
explanations for this disconcerting result have not been provided to date.
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It is well established that cardiovascular function is under P-adrenergic control
and J3-blockers are widely used for the clinical management of hypertension and heart
disease (26). In light of our recent in vitro and in vivo findings on the P-adrenergic
regulation of PAC, we therefore hypothesized that the chemopreventive agents used in
the CARET trial may have promoted the development of PAC via stimulation of a
signaling component of its P-adrenergic regulatory pathway. An extensive literature
search revealed that P-carotene has been shown to increase intracellular cAMP in
neuroblastoma cells (27). Our current experiments have therefore focused on the effects
of P-carotene on cAMP and its associated downstream pathways as potential mediators of
a stimulating effect on the proliferation of a human Clara cell-derived PAC cell line and
its putative cell of origin (immortalized human small airway epithelial cells). Our data
provide strong evidence in support of the hypothesis that P-carotene stimulates the
growth of these cells via an increase in intracellular cAMP, activation of protein kinase
A, activation of the cAMP response element (CREB) and activation of the extracellular
signal-regulated kinases (ERK1/2 ).
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Materials and Methods
Cell lines and tissue culture
The human PAC cell line with characteristics of Clara cells, NCI-H322, was
purchased from the Center for Applied Microbiology and Research (ECACC, Salisbury,
Wiltshire, UK). NCI-H322 cells were maintained in RPMI-1640 medium containing
10mM HEPES; l mM sodium pyruvate; 2mM L-glutamine; 4500 mg glucose/L; and
1500 mg sodium bicarbonate/L), supplemented with 10% fetal bovine serum (FBS) but
without supplement of antibiotics. The Simian virus 40 (SV40)-immortalized human
peripheral airway cell line HPL1D (28), referred to in this publication as small airway
epithelial cells SAEC, was provided to us by Dr. Takashi Takahashi (Aichi Cancer
Center Research Institute, Nagoya University, Chikusa-ku, Nagoya 464, Japan). These
cells were maintained in F-12 (HAM) medium buffered with 1 5mM HEPES (pH 7 .3;
Gibco Invitrogen-Life Technologies, Carlsbad, CA) and supplemented with 5µg/ml
bovine insulin, 5µg/ml human transferrin, 10·7 M hydrocortisone, 2 x10· 10 M triiodo
thyronine (Cambrex Bio Science Walkersville, Inc, Walkersville, MD) and 1% fetal calf
serum (FCS; ATCC, Manassas, VA). No antibiotic was added. The SV40/adinovirus/12
hybrid virus immortalized human bronchial epithelial cell line BEAS-2B was obtained
from the American Type Culture Collection (Rockville, MD). These cells were
maintained in bronchial epithelial cell basal medium (BEBM) supplemented with 2ml
BPE, 0.5ml insulin, bovine (5mg/ml), 0.5ml HC, 0.5 ml retinoic acid, 0.5ml transferrin,
0.5ml T3, 0.5ml epinephrine, 0.5ml HEGF (Cambrex Bioscience Walkersville, MD)
and without supplement of antibiotics.
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cAMP Immunoassay

The level of cAMP in cell lysates was determined with a direct cyclic AMP
Correlate- EIA TM kit (Assay Design, Ins., Ann Arbor, Ml), according to the instructions
by the manufacturer. Briefly, in this competitive binding assay the cyclic AMP present in
a sample competes with a fixed amount of alkaline phosphatase-labeled cyclic AMP for
sites on a rabbit polyclonal antibody to cyclic AMP.

During the incubation, the

polyclonal antibody is bound to a goat anti-rabbit antibody coated on the microplate.
Following a wash to remove excess conjugate and unbound sample, a substrate solution,
p-nitrophenyl phosphate, is added to the wells to determine the bound enzyme activity.
The color development is stopped with a solution of trisodium phosphate after an hour of
incubation and the absorbance is read at 405 nm. The intensity of the color is inversely
proportional to the concentration of cyclic AMP in the sample.
NCI H322 cells or SAECs were seeded into 6-well plates (Falcon, Franklin Lakes,
NJ, USA) at 4 x 1 05 cells/ well in their individual media as specified above and
maintained in an environment of 3 7°C, 5% CO2 until they had reached 65-70 confluence.
The media were then removed and replaced by low serum medium (0. 1 % FEBS) for
NCI-H322 cells or basal F- 1 2 medium (0.05% FBS) without additives for SAECs to
starve the cells for 24 hours. The cells were then washed twice with l X PBS and
preincubated with fresh RPMI- 1 640 medium (0. 1 % FBS) for NCI-H322 cells or F- 12
medium (0.05% FBS) for SAECs containing 3-isobutyl- 1 -methylxanthine (lmM) for 30
minutes. Following removal of this preincubation mix, the cells were incubated for 1 0 or
30 minutes with P-carotene type 1 (20 nM, Sigma, Louis, MO, USA) in fresh media
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containing l mM IBMX in an atmosphere of 37°C , 5% CO2. Following 3 washes with
sterile distilled water, the cells were then incubated with 600 µl of O. l M HCL for 20-3 0
minutes and scraped off the well surfaces with a plastic scraper (Fisher Scientific, GA,
USA). The cell lysates were collected into 1 .5ml Eppendorf tubes and stored in ice.
Following sonication of the cell lysates at 40 rpm for 1 0 seconds (Fisher Sonic
Dismembrator. Model 300), the samples were immediately analyzed using the standard
non-acetylated version of the cAMP enzyme immunoassay kit, according to the
manufacturer's instructions. Each experiment was repeated three times. Data are
expressed as mean values and standard errors of three independent experiments, each
conducted with triplicate samples per treatment group. Statistical analysis of data was by
one-way ANOV A, Tukey-Kramer multiple comparison test and two-tailed unpaired t
test. Following statistical analysis, data were normalized with controls set as 1 00% for
documentation as column graphs.

PKA activation assay

Following incubation of cells with P-carotene (20 nM) for 5 minutes to 2 hours
as specified in the figure legends, PKA activity was assayed in cell lysates using a Pep
Tag assay for non-radioactive detection of activated

PKA (Promega Corperation,

Madison, WI, USA), following the instruction of the manufacturer. Tubes containing
the catalytic subunit of PKA (provided with the kit) served as positive controls.This
assay utilizes fluorescent substrate for PKA that changes the peptide's net charge upon
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phosphorylation of PKA, thus allowing the phopsorylated peptide to migrate to the
positive electrode (+), while the non-phosphorylated peptide migrates to the negative
electrode (-). All samples were kept on ice. At time zero, the samples were removed
from the ice and incubated in a water bath at 30°C for 1 minute. A 1-10 µI aliquot from
each sample was added to the reaction cocktail (5µ1 PEP Tag PKA reaction 5X buffer, 5
µI Pep Tag A1 peptide, 5 µI PKA activator 5X solution, 1 µI peptide protection
solution) and incubated for 30 minutes at room temperature. The reaction was stopped
by placing all samples into a boiling water bath or at 95°C in a heating block for 10
minutes. All samples were stored at -20°C in the dark until loading into 0.8% agarose
gels (GIBCOBRL, Grand Island, N.Y, USA; 100 V for 15-18 minutes) in the presence
of 50mM Tris-HCL (pH 8) (Fisher Biotech, Fair Lawn, New Jersey), using a Gel XL
Plus Electrophoresis System (Labnet International, Inc., Woodbridge, NJ), following
the addition of 1 µI of 80% glycerol per sample. An electronic transilluminator camera
(Ultra Lum, Inc., Paramaount, CA) was used to view and capture the images for
densitometric analysis (Scion software for image quantitation, NIH). Each experiment
was conducted independently under identical conditions three times with similar results.
Data are expressed as mean values and standard errors of three independent
experiments, each conducted with triplicate samples per treatment group. Statistical
analysis of data was by one-way ANOVA, Tukey-Krarper multiple comparison test and
two-tailed unpaired t-test. Following statistical analysis, data were normalized with
controls set as 100% for documentation as column graphs.
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Western blotting ofproteins and phosporylated proteins
To assess the effects of �-carotene on the expression and phosphorylation of
the mitogen activated protein kinases ERK.1/2 or the cAMP response element binding
protein CREB, 500,000 NCI-H322 or SAEC cells were seeded into culture vessels ( 1 00
cm2) containing their respective growth media. When the cells had reached 60-65%
confluence, they were rinsed one time with lX PBS and serum-starved for 24 hours.
Following removal of the media and replacement with fresh low-serum media, �
carotene (20 nM) was added to the culture vessels and cells were incubated from 5
minutes to 2 hours as detailed in the figure legends. Cells exposed to the �-carotene
vehicle (dimethylsulfoxide) served as controls. The cultured cells then were washed
once with cold PBS, and were mixed with an appropriate volume of cell lysis buffer
containing 20mM Tris-base, 200mM NaCL, l M Sodium Floride, 0.5M EDTA, l OOmM
Na3 V04, l OOmM PMSF, 1 µ1/ml of pepstatin A, 1 µ1/ml of leupeptin, 1 µ1 of aprotinin
(protease inhibitor, Sigma-Aldrich, St. Louis, MO) and 0.25% NP-40 (Calbiochem, La
Jolla, CA). The cells were reincubated with lysis buffer at 4°C for 20-30 minutes in the
refrigerator and were then scraped off. The cell lysates were collected into 1 .5ml
Eppendorf tubes and kept on ice. The lysates were vortexed for 1 0 minutes and stored in
liquid nitrogen for 1 minute then thawed for 2 cycles. The lysates were clarified by
centrifugation at 1 5,000 x g for 30 minutes at 4°C and the protein concentration was
determined using a BCA protein assay kit (Pierce, Rockford, IL). Samples were boiled
with 4X SDS sample protein loading buffer containing 200mM Tris-Hcl (pH 6.8),
l OOmM DTT, 8% SDS, 0.5 -0. 1 % bromophenol blue, and 40% glycerol (Sigma56

Aldrich, St. Louis, MO). Prestained protein marker, broad range (New England Biolabs,
Inc., Beverly, MA) and 20-30 µg of protein samples were loaded/ lane and running
buffer for protein sample separation (Bio-Rad, Alfred Nobel Drive, Hercules, CA). This
gel was transferred in methanol (Fisher Scientific), and distilled water at 1 OOV for 1
hour then washed one time with l X TBST (200mM Tris-HCL and 1 .5M NACL per
liter) and 0.05% tween-20 (Sigma). Membranes were blocked in 1 0ml of 5% non-fat
dry milk (Kroger) in lX TBST for 1 hour. Membranes were then incubated over night
at 4°C with primary antibodies (rabbit antibody for total ERKl /2, rabbit Thr202/Tyr204
for phospho-Erkl /2, each at a 1 : 1 000 dilution; Cell Signaling Technology, Beverly,
MA). As a control for equal loading of the lanes, a monoclonal anti-actin clone (Ac-74,
mouse source, Sigma-Aldrich, St. Louis, MO) was used at a 1 : 1 000 dilution. At the end
of the incubation period, five five-minute washes were done with l X TBST.
Membranes were further incubated with the secondary antibodies in 1 0ml of 5% non-fat
dry milk in TBST at room temperature for one hour. The secondary antibodies,
Alexflour 680 goat-anti-rabbit IgG (Probes Eugene, Oregon, USA) and IRDye 800
conjugated affinity purified anti-mouse IgG (Rockland Immunochemicals, Inc.,
Gilbertsville, PA) were used at 1 :2500 dilution and 1 :5000 dilution respectively.
Membranes were then rinsed five times five-minutes each with l X TBST. An Odyssey
scanner and software (Lincoln, Nebraska, USA) were used for membrane scanning and
visualization of bands. The same cell lysates and methods were used to assess the
effects of �-carotene on CREB and phosphorylated CREB. A rabbit polyclonal CREB
antibody (Cell Signaling Technology, Beverly, MA) was used as a primary antibody for
total CREB (dilution 1 : 1 000), while a monoclonal mouse antibody that recognizes
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SER33 of phosphorylated CREB (Cell Signaling Technology, Beverly, MA) was used
to probe for the activated form of CREB (dilution 1 : 1000). Each Western blot was
repeated three times under identical conditions and yielded similar data. Data are
expressed as mean values and standard errors of three independent experiments, each
conducted with triplicate samples per treatment group. Statistical analysis of data was
by one-way ANOVA, Tukey-Kramer multiple comparison test and two-tailed unpaired
t-test. Following statistical analysis, data were normalized with controls set as 100% for
documentation as column graphs.

MTT assayfor the assessment of cell numbers
The effects of �-carotene on cell proliferation were assessed by the colorimetric
3-(4, 5-dimethyle thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (2)
(Sigma-Aldrich Co., St. Louis, MO, USA. Briefly, the MTT test is based on the NADH
dependent enzymatic reduction of the tetrazolium salt MTT [3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-tetrazoliumbromide] in metabolically active cells but not in dead cells.
Cells were seeded into 6-well tissue culture plates (Falcon, Franklin Lakes, NJ, USA) at
a density of 50,000 cells per well for NCI-H322, and 50,000 cells per well for SAEC
and BEAS-2B cells. The cells were left to grow in complete media at 37°C with 5%
CO2 for 5 hours to attach. The cells were then switched to fresh low serum media and
�-carotene was added at the concentrations specified in the figure legends and incubated
for 72 hours. Pre-icubation of cells with inhibitors of adenylyl cyclase (SQ22536, 500
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nM) or of ERKl/2 (PD98059, 1 µM) for assays documented in the inset of Figure 5 was
for 10 minutes. Fresh low serum medium of each cell line and fresh treatment were
added every other day. After treatment for 68 hours 50µ1 of [3-(4, 5-dimethyl thiazol-2yl)-2, 5-diphenyl tetrazolium bromide (0.5mg/ml) was dissolved in RPMI-1640 with L
glutamine and phenol-free medium (Gibco Invitrogen Corporation, Grand Island, N.Y,
USA)], added to the medium and incubated at 37°C in the incubator for another 2-3,
allowing for the metabolic conversion of the MTT substrate to blue formazan. The
media were then discarded and 550 µl of Isopropanol (2-propanol UV cutoff 205 nm,
Fisher Scientific, GA, USA) was added to the wells. Absorbances at 570 nm and 630
nm in each well were measured on a micro-ELISA reader. Data are expressed as mean
values and standard errors of three independent experiments, each conducted with four
samples per treatment group. Statistical analysis of data was by one-way ANOVA,
Tu.key-Kramer multiple comparison test and two-tailed unpaired t-test. Following
statistical analysis, data were normalized with controls set as 100% for documentation
as column graphs. Data in the inset of Figure 5 that illustrates the effects of an adenylate
cyclase inhibitor or an inhibitor of MEK on the stimulation of cell proliferation by
carotene were normalized with P-carotene-stimulated cells set at 100%.
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Results

We have previously shown that the proliferation of human PAC cells of Clara cell
lineage in vitro and the development of this cancer type in NNK-treated hamsters is under
P-adrenergic control ( 14-17). Moreover, our recent immunohistochemical studies have
documented selective over-expression of PKA, phosporylated CREB and phosphorylated
ERK.1/2 in the NNK-induced PACs (29). The activation of cAMP, PKA and CREB are
classic events downstream of P-adrenergic receptor stimulation in many cell types
unrelated to cancer (30-32). Similarly, activation of ERKl/2 has been reported as an
effector of CREB or PKA in some cells (3 3-35). Taken together, our published data
therefore point to an important role of cAMP, PKA, CREB and ERK.1/2 in the growth
regulation of PAC of Clara cell linage in humans and in the hamster model. In an effort to
understand the reasons for the unfortunate outcome of the CARET trial, we therefore
tested the hypothesis that P-carotene may stimulate one or several components of this
regulatory pathway.
Exposure of the putative cells of origin of pulmonary adenocaricnoma, SAECs, to
P-carotene (20 nM) caused a significant and time-dependent increase in intracellular
cAMP as assessed by immunoassay (Figure 1). This response peaked after 10 minutes of
exposure with a 1.6-fold increase. The response of the human PAC cell line NCI-H322 to
an identical exposure of P-carotene was even more pronounced with a 2.5-fold increase
of intracellular cAMP after 10 minutes of exposure (Figure 1). The observed stimulation
of cAMP was reproducible as assessed by three independent experiments that yielded
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similar results, each with three samples per treatment group. Statistical evaluation of the
data by one-way ANOVA, Tukey-Kramer multiple comparison test and paired two-tailed
t-test established significant differences between control and treatment groups as
specified in the figure legends.
Assessment of PK.A activation by a non-radioactive kit that measures the
migration of the phosphorylated peptide to the positive electrode(+), while the non
phosphorylated peptide migrates to the negative electrode (-), revealed a time-dependent
increase in activated PK.A of SAECs exposed to J3-carotene (20 nM; Figure 2) with a
maximum 2.6-fold increase at the 1 hour time interval (Figure 2). Similarly, the human
PAC cell line NCI-H322 responded to 20 nM of J3-carotene with a time-dependent
increase of PK.A activity that peaked at a 1 .6-fold increase (Figures 2a, b ). In both cell
systems, the observed increase in PK.A activity was highly significant (p< 0.001 by one
way ANOVA, Tukey-Kramer multiple comparison test and unpaired, two-tailed t-test
from triplicate samples per treatment group of three independent experiments).
The effects of J3-carotene (20 nM) on expression levels of the transcription factor
CREB and its phosphorylated form were assessed by Western blot analysis (Figure 3).
SAECs demonstrated a time-dependent increase in p-CREB protein with the highest level
(4.7-fold increase) observed after 120 minutes of exposure (Figure 3). NCI-H322 cells
were even more responsive to J3-carotene with a 4.8-fold increase in p-CREB observed
after 5 minutes of exposure and peak values of 8.7-fold after 1 hour (Figure 3) In neither
cell line did exposure to J3-carotene increase the levels of unphosphorylated CREB
protein (Figure 3 ). The observed increases in p-CREB expression were highly significant
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in both cell systems at all time intervals tested (p<0.00 1 by one way ANOVA, Tukey
Kramer multiple comparison test and two-tailed unpaired t-test from mean values and
standard errors of densitometric values from three independent experiments conducted
under identical conditions, each with triplicate samples).
The effects of �-carotene (20 nM) on the mitogen-activated kinases ERK. 1/2 and
their phosphorylated forms were also assessed by Western blotting. As exemplified in
Figure 4, p-ERK. 1/2 was significantly increased in SAECs at all time intervals tested with
a 2.5-fold increase as early as 5 minutes after exposure to �-carotene and a peak value of
4.6-fold at the 30 minute time interval (Figure 4). The response of the cancer cell line
NCI-H322 to �-carotene was even more pronounced with a 4.8-fold increase in p
ERK.1/2 expression after 5 minutes of exposure to �-carotene and a peak level of 7.8-fold
at the 1 hour time interval (Figure 4). The observed increases in p-ERK. 1/2 in both cell
lines cells were highly significant at all time intervals tested (p<0.00 1 ) by one-way
ANOV A, Tukey-Kramer multiple comparison test and two-tailed unpaired t-test from
densitometric values of three independent experiments conducted under identical
conditions, each with triplicate samples. Beta-carotene did not increase the expression of
unphosphorylated ERK. 1/2 protein in either cell system at any of the time intervals tested.
The potential role of the observed changes in cAMP, PKA, and phosporylated
proteins on cell proliferation was assessed by MIT assays. In our published studies on
the growth-stimulating effects of �-adrenergic agonists and cAMP on NCI-H322 cells we
used [3H]-thymidine incorporation assays that monitor DNA synthesis ( 14, 1 5). Because
the MTT assay monitors numbers of viable cells which can be influenced by both, cell
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proliferation and apoptosis, the results of the MTT assays were verified by [3H]thimidine
incorporation assay with controls versus three concentrations (1 pM, 10 pM, 100 pM) of
�-carotene (data not shown). We tested the effects of �-carotene on cell numbers in the
MTT assay after 24, 48 or 72 hours of incubation. While the stimulating effects of �
carotene were highly significant at all time intervals tested, the responses after 72 hours
of exposure were the most dramatic and are therefore illustrated in Figure 5. Our data
show that �-carotene caused a dramatic increase in the numbers of SAECs at all
concentrations, an effect that peaked with a 13-fold increase after incubation with a 10
pM concentration. Similarly, the cancer cells NCI-H322 were highly responsive to the
growth-stimulating effects of �-carotene, an effect that peaked with a 12.3-fold increase
at a 100 pM concentration of �-carotene (Figure 5). The stimulatory effects of �-carotene
on cell proliferation in both cell systems were highly significant (p< 0.001) by one way
ANOVA, Tukey-Kramer multiple comparison test and two-tailed unpaired t-test. Pre
incubation of the cells for 10 minutes with the adenylyl cyclase inhibitor SQ2536 (500
nM) reduced the stimulating effects of �-carotene (20 nM) in SAECs and NCI-H322 cells
to 27 and 32%, respectively (with fully �-carotene-stimulated cells set at 100%; Figure 5,
inset). On the other hand, pre-incubation for 10 minutes with the MEK inhibitor
PD98059 (10 µM) completely blocked the response of SAECs to �-carotene while
reducing the response of NCI-H322 cells to 28% (Figure 5, inset). These data support our
interpretation that the observed stimulating effects of �-carotene on the proliferation of
SAECs and NCI-H322 cells was mediated by c-AMP-dependent signaling and activation
of ERK.1/2.
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Because the preclinical studies leading to the CARET trial had emphasized
inhibiting effect of �-carotene on the development of chemically induced tumors derived
from the upper airways of laboratory animals, we assessed the effects of �-carotene on
immortalized human large airway epithelial cells (BEAS-2B) by MTT assay. In support
of the original reports in hamster models, our data show a concentration-dependent
decrease in cell number when BEAS-2B cells were exposed for 72 hours to �-carotene
(Figure 6). The growth-inhibiting effects of �-carotene on these cells was highly
significant (p< 0.001 by one way ANOVA, Tukey-Kramer multiple comparison test and
two-tailed unpaired t-test from 4 samples per treatment group of three independent
experiments).
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Discussion

The pro-vitamin �-carotene is converted in the mammalian organism to vitamin
A. The majority of functions of vitamin A are carried out by its metabolite, retinoic acid
(36), a transcriptional activator operating primarily through members of the nuclear
receptor family of transcription factors (37). Synthetic retinoids continue to be widely
studied as potential preventive and/or therapeutic agents for a variety of cancers (38-42)
or disorders of the nervous system such as Parkinson's disease, motoneuron disease and
Huntington's disease (37). In addition to the original preclinical studies on the prevention
of cancer development from epithelia of the upper airways (20, 43-45), current research
primarily concentrates on the use of retinoids for the prevention and/or therapy of head
and neck cancer (40) or leukemia (41, 42). It remains undisputed that �-carotene and
retinoids do have beneficial effects via inhibition of cell proliferation and/or stimulation
of apoptosis in cancers of those cell lineages. In fact our MTT assay with the human large
airway epithelial cells BEAS-2B confirm that. However, our data also provide
compelling evidence for cell type-specific growth-stimulating effects of �-carotene on
human PAC cells and their normal cells of origin (SAECs) via increase in intracellular
cAMP, activation of PKA as well as phosphorylation of CREB and ERKl/2. In light of
the prevalence of PAC, these novel and hitherto unknown mechanisms of action of �
carotene should be considered as key factors responsible for the unfortunate outcome of
the CARET trial. This interpretation gains strong support from the fact that both, lung
cancer and cardiovascular deaths were significantly increased in the CARET trial ( 1 9).
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As we have previously pointed out, PAC and cardiovascular disease not only share the
same risk factors (smoking and high-fat diet) but they are also both regulated by P
adrenergic receptor-initiated and cAMP-mediated signal transduction pathways (46).
While it is far from understood which cellular mechanisms caused the increase in
intracellular cAMP in response to P-carotene in our experiments, a similar effect of this
pro-vitamin has been reported in neuroblastoma cells (27). It has also been shown that
exposure of myeloid leukemia cells to a phosphodiesterase inhibitor that increased
intracellular cAMP and activated PKA potentiated the cytodifferentiating action of
retinoids (41). The dramatic increase in activated PKA, CREB and ERK.1/2 observed m
SAECs and PAC cells exposed to P-carotene in our experiments is particularly intriguing.
While phophorylation of ERK.1/2 is a key event downstream of numerous signaling
pathways in many types of cancer (47-52), a potential growth-stimulating role of PKA
and its downstream transcription factor CREB in cancer cells has been given little
attention. To our knowledge, activation of PKA/CREB has only been implicated in the
development of endocrine tumors (31 ). On the other hand, recent immunohistochemical
studies conducted by us in NNK-induced PACs in hamsters have shown a strong and
selective over-expression of PKA, phosphorylated CREB and phosphory lated ERK1/2 in
the tumor tissue (29). Further studies are clearly needed to address the role of the
cAMP/PKA/CREB pathway and its potential cross-talk with other signaling pathways in
human PAC.
The growth-stimulating effects of P-carotene observed in SAECs and PAC cells
are in accord with published data that have documented a stimulation of cell proliferation
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of human PAC cells in vitro in response to agents that increase intracellular cAMP (14,
15). A cancer promoting effect of agents that increase intracellular cAMP has also been
documented in a hamster model of PAC induced by the tobacco-specific carcinogen
NNK (16, 17). By contrast, such agents inhibited the growth of human PAC cells of
alveolar type II cell lineage (15)

or human small cell lung cancer cells (53) and

demonstrated significant cancer preventive effects in a hamster model of NNK-induced
neuroendocrine lung tumors (17).
Collectively, our current data and published evidence emphasize the fact that
identical pathways can have very different functions in different cell types and in cancers
of different cell lineages. Strategies that target regulatory signal transduction pathways
for the prevention and therapy of cancer have to carefully consider this. Unless suitable
diagnostic tools are developed that identify which signaling pathway is hyperactive in
individual patients, clinical trials aimed at modulating signal transduction will continue to
yield disappointing results.
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Summary

A multinational chemoprevention trial with B-carotene and retinoids (B-carotene
and retinoid efficacy "CARET" trial) was conducted in the 1 990s in populations at risk
for the development of lung cancer because of previous or current exposure to smoking
or asbestos. The trial had to be discontinued after 5 years due to a 28% increase in lung
cancer incidence and mortality (46%) and a 26% increase in cardiovascular mortality.
The current experiments represent a first step towards unraveling the reasons for this
disappointing outcome.
Using a cell line derived from a human pulmonary adenocarcinoma of Clara cell
lineage and immortalized human small airway epithelial cells; our data show that low
concentrations of B-carotene that can be realistically expected in human tissues after oral
administration caused a significant increase in intracellular cAMP, activated PKA, as
well as in phosporylation of ERK. 1/2 and CREB. Furthermore, the proliferation of cells
was significantly stimulated by identical concentrations of B-carotene as monitored by
MTT assays.
These data are in accord with our earlier publications that have identified a beta
adrenergic receptor-initiated growth-regulating pathway with cAMP as a downstream
effector in human pulmonary adenocarcinomas of Clara cell lineage in vitro and in a
hamster model. In light of the fact that pulmonary adenocarcinoma is the leading type of
lung cancer, these findings suggest that the growth promoting effects of B-carotene on
this cancer type observed in our experiments was an important factor responsible for the
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unfortunate outcome of the CARET trial. This interpretation is supported by the fact that
elevated levels of cAMP in the cardiovascular system play a major role in the genesis of
cardiovascular disease, which was also greatly promoted in the CARET trial.
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APPENDIX
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Figure 1. Effects of �-carotene (20 nM) on intracellular cAMP accumulation in
SAEC and NCI-H322 cells. Following a 24 hour starvation period, the cells were
incubated for 10 or 30 minutes with �-carotene. Cells in the control group were
treated with the vehicle of P-carotene (DMSO). Analysis of cAMP was by
competitive binding assay as outlined in the Materials and Methods. Bars
represent mean values and standard errors of triplicate samples from three
independent experiments expressed as normalized data ( controls were set as 100% ). Statistical analysis of data was by one-way ANOVA, Tukey-Kramer multiple
comparison test and two-tailed unpaired t-test. The increase in intracellular cAMP
was significant (p<0.05 and 0.01) for SAECs at both time intervals tested and
were significant (p<0.01) for NCI-H322 cells at the ten minute time interval.
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Figure 2A. Agarose gel exemplifying the effects of �-carotene (20 nM) on
phosphorylation of PKA in SAECs and NCI-H322 cells. Following a 24 hour
starvation period, the cells were exposed to �-carotene for the indicated times.
PKA activity was then assayed in cell lysates using a Pep Tag assay for non
radioactive detection of PKA and the samples were separated on an 0.8% agarose
gel. Phosphorylated peptide migrated towards the positive electrode (+Ve), while
non-phosphorylated peptide migrated towards the negative electrode (-Ve).
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Figure 2B. Bar graph illustrating densitometry values of the bands in Figure 2A.
Densitometric analysis was performed using the NIH Scion software for image
quantitation. Bars represent normalized (control values set at 100%) mean values
and standard errors of three independent experiments, each with triplicate
samples. Statistical analysis of data was by one-way ANOVA, Tukey-Kramer
multiple comparison test and two-tailed unpaired t-test. The observed increases in
phosphorylated PKA were significant (p<0.001) at all time intervals tested in the
SAECs and after 5, 15, and 30 minutes of exposure in NCI-H322 cells.
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Figure 3A. Western blot exemplifying the effects of �-carotene (20 nM) on the
expression of phosphorylated CREB and total CREB protein in SAECs. Following a
24 hour starvation period, cells were exposed to b-carotene for the time intervals
indicated. The bands for p-CREB increased in size and density over time whereas no
increase was observed in the bands for total CREB protein.
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Figure 3B. Western blot exemplifying the effects of �-carotene (20 nM) on the
expression of phosphorylated CREB and total CREB protein in NCI-H322 cells.
Following a 24 hour starvation period, cells were exposed to �-carotene for the
time intervals indicated. The bands for p-CREB increased in size and density over
time whereas no increase was observed in the bands for total CREB protein.
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Figure 3C. Bar graph illustrating densitometry values of the bands in Figures 3A and
3B. Densitometric analysis was performed using the NIH Scion software for image
quantitation. Bars represent normalized (control values set at 100%) mean values and
standard errors of three independent experiments, each with triplicate samples.
Statistical analysis of data was by one-way ANOVA, Tukey-Kramer multiple
comparison test and two-tailed unpaired t-test. The observed increases in p-CREB
were significant (p<0.001) in both cell systems at all time intervals tested.
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Figure 4A. Western blot illustrating the effects of �-carotene (20 nM) on the
expression of ERKl/2 and its phosphorylated form in SAECs. Cells were exposed to
�-carotene for the time intervals indicated after a 24 hour starvation period. The
bands for p-ERKl/2 increased in size and intensity, an effect that peaked after 30
minutes of incubation whereas the expression of ERK 1 /2 did not increase.
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Figure 4B. Western blot illustrating the effects of �-carotene (20 nM) on the
expression of ERKl/2 and its phosphorylated form in NCI-H322 cells. Cells were
exposed to �-carotene for the time intervals indicated after a 24 hour starvation
period. The bands for p-ERK1/2 increased in size and intensity, an effect that peaked
after 1 5 minutes of incubation whereas the expression of ERK 1 /2 did not increase.
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Figure 4C. Bar graph illustrating densitometry values of the bands in Figures 4A and
4B. Densitometric analysis was performed using the NIH Scion software for image
quantitation. Bars represent normalized (control values set at 1 00%) mean values and
standard errors of three independent experiments, each with triplicate samples.
Statistical analysis of data was by one-way ANOVA, Tukey-Kramer multiple
comparison test and two-tailed unpaired t-test. The observed increases in p-ERKl/2
were significant (p<0.00 1 ) in both cell systems at all time intervals tested.
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Figure 5. Effects of P-carotene (l pM-200 nM) on cell number in SAECs and NCI
H322 as assessed by MTT assay. The cells were left to grow in complete media for 5
hours to attach. The cells were then switched to fresh low serum media (0.05% FBS)
for SAECs and (0.1% FBS) for NCI-H322 cells. Cells were then exposed for 72 hours
to P-carotene at the concentrations indicated. Bars represent normalized (control
values set at 100%) mean values and standard errors of three independent
experiments, each with four samples per group. Statistical analysis of data was by
one-way ANOVA, Tukey-Kramer multiple comparison test and two-tailed unpaired t
test. The observed increases in cell number were significant (p<0.001 ) at all
concentrations tested in both cell systems.
Inset: Inhibitory effects of the adenylase cyclase inhibitor SQ2536 (500 nM) or the
MEK inhibitor PD98059 (10 µM) on P-carotene induced cell numbers as assessed by
MTT assay. Following a 24 hour starvation period, cells were pre-incubated for ten
minutes with the inhibitors and then exposed for 72 hours to P-carotene. The
stimulatory response to P-carotene was significantly reduced (p<O.001) by both
inhibitors in both cell systems. Bars represent normalized (cells treated with P
carotene alone set as 100%) mean values and standard errors of three independent
experiments, each with triplicate samples.
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Figure 6. Effects of �-carotene (l pM-2µM) on cell number in BEAS-2B cells as
assessed by MTT assay. The cells were left to grow in complete media for 5 hours to
attach. The cells were then switched to fresh low serum media (0.05% FBS). Cells
were exposed for 72 hours to �-carotene at the concentrations indicated. Bars
represent normalized (control values set at 100%) mean values and standard errors of
three independent experiments, each with four samples per group. Cell numbers were
significantly reduced at all concentrations tested (p< 0.001 by one way ANOVA,
Tukey-Kramer multiple comparison test and two-tailed unpaired t-test).
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PART IV:
Theophylline stimulates cAMP-mediated signaling associated
with growth regulation in human cells from pulmonary
adenocarcinoma and small airway epithelia
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Part IV
Brief explanatory statement
This chapter is a lightly revised version of a manuscript by the same name that has
recently been submitted to the journal "International Journal of Oncology".
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contributions to this paper include ( 1 ) selection of the topic, (2) development of assay
conditions suitable to test the hypothesis that theophylline stimulates the growth of
pulmonary adenocarcinoma cells and their normal cells of origin, (3) conduction of
cAMP assays, (4) conduction of PKA activation assays, ( 5) conduction of Western blots,
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analysis of all data, (9) photographic and graphic documentation of results, ( 1 0)
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some editorial assistance by Dr. Schuller).
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Introduction
Preclinical studies in mouse models of lung cancer have demonstrated that green
tea as well as black tea inhibit the development of experimentally induced lung adenomas
and that this effect is largely caused by polyphenols of the catechin family that have
antioxidant, anti-mutagenic, pro-apoptotitc and anti-proliferative effects in this animal
model (1-4). However, epidemiological studies on the effects of tea

in human

populations have been inconclusive with some showing a reduction in lung cancer risk
while others demonstrated no effect or even cancer promoting effects (5-7).
Unfortunately, none of the epidemiological investigations have specified the effects of tea
on histological lung cancer types. Among the four major histological lung cancer types
(adenocarinoma, small cell lung carcinoma, squamous cell carcinoma, large cell
carcinoma), pulmonary adenocarcinoma (PAC) is the leading type of lung cancer today
(8, 9). Even though mouse lung adenoma is a model for human PAC, it is well
established that these mouse tumors are derived from alveolar type II cells (10, 11). By
contrast, electron microscopic investigations have provided evidence for about 90% of
human PACs to be derived from bronchial and bronchiolar Clara cells (PACC) with only
about 10% of cases exhibiting characteristics of alveolar type II cells (12). Accordingly,
preclinical data generated in the mouse models cannot be extrapolated to about 90% of
cases of the leading type of human lung cancer (PACC).
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Studies conducted in our laboratory have shown that human cell lines derived
from PACC as well as experimentally induced PACC in hamsters are under �-adrenergic
growth control (1 3- 1 6). Pharmacological agonists of � -adrenergic receptors as well as
forskolin, which stimulates the downstream effector of this receptor family, cAMP, each
demonstrated strong promoting effects on human P ACC cell growth in vitro and on the
development of P ACC in hamsters. We have also shown that a cell line derived from
human PAC of alveolar type II cell lineage responded with an inhibition in cell
proliferation to forskolin ( 1 6). These findings suggest that within the family of human
PACs the predominating Clara cell derived tumors respond with increased growth to
cAMP whereas the rare PAC of alveolar type II cell lineage is inhibited. Accordingly,
any agents that increase intracellular cAMP have the potential to act as tumor promoters
for the development of PACC.
Theophylline is a methylxanthine contained in tea products and in numerous
medications for the treatment of asthma, cough and the common cold ( 1 7). Among the
tea products that contain theophylline are grean tea, black tea, mint tea (all in their
caffeinated and decaffeinated forms) as well as numerous dietary supplements that are
based on green tea extracts and which are widely used as weight control medicines. It is
well established that theophylline inhibits the enzyme phopsphodiesterase that mediates
the cellular break-down of cAMP (1 7). Consequently, exposure to theophylline results in
intracellular accumulation of cAMP. It is therefore reasonable to assume that signaling
pathways downstream of cAMP will be stimulated by theophylline. In light of the tumor
promoting effects of cAMP on human and hamster PACC discovered by us, theophylline
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may therefore selectively promote the growth and development of this form of lung
cancer.
In support of this hypothesis, our current data in cell lines derived from human
PACC and its cell of origin (SAEC) show that theophylline increased intracellular cAMP
resulting in the activation of its downstream kinase, protein kinase A (PKA) and its
associated transcription factor cAMP response element binding protein (CREB) as well
as phosphorylation of the mitogen-activated protein kinases ERK.1/2.
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Materials and Methods
Cell lines and tissue culture
The human PAC cell line with characteristics of Clara cells, NCI-H322 (Center
for Applied Microbiology and Research (ECACC, Salisbury, Wiltshire, UK) was
maintained in RPMI-1640 medium (Gibco Invitrogen-Life Technologies, Carlsbad, CA)
supplemented with 10% FBS, 10 mM Hepes, lmM sodium pyruvate, 2mM L-glutamine,
4500 mg/I glucose, and 1500mg/I sodium bicarbonate. The Simian virus 40 (SV 40)
immortalized human peripheral airway cell line HPL l D (18), referred to in this
p ublication as small airway epithelial cells SAEC, was provided to us by Dr. Takashi
Takahashi (Aichi Cancer Center Research Institute, Nagoya University, Chikusa-ku,
Nagoya, Japan). These cells were maintained in F-12 (HAM) medium buffered with
15mM HEPES (pH 7.3; Gibco Invitrogen-Life Technologies, Carlsbad, CA) and
supplemented with 5 µg/ml bovine insulin, 5µg/ml human transferrin, 1 f 7 M
f

hydrocortisone, 2 x10- 10 M triiodothyronine (Cambrex Bio Science Walkersville, Inc,
Walkersville, MD) and 1% fetal calf serum (FCS ; ATCC, Manassas, VA). No antibiotic
was added.

cAMP Immunoassay
Cells were plated at 4

x

10 5 cells per well in 6-well plates and grown in F-12

media with supplements and 1 % FBS for SAECs or in RPMI-1640 containing 10% FBS
until 65-70 % confluence. Then cells were then washed twice with I X PBS and then fed
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with low serum (0.05% FBS) for SAECs and (0. 1 % FBS) for NCI-H322 cells or no
serum medium for 24 hours starvation. Fresh low serum media of F 1 2 (0.05% FBS) or
RPMI media (0. 1 % FBS) containing lmM IBMX, a phosphodiesterase inhibitor was
added to all treatment and control group and pre-incubated for 30 minutes. After removal
of this pre-incubation mix, the cells were incubated and treated with the concentrations of
theophylline indicated in the figure legend in the appropriate medium containing l mM
IBMX for 1 0 minutes. After three washes with water, cells were incubated with 0. 1 M
HCL lysis buffer for 20-30 minutes, and then the cells were scraped by plastic scraper
and collected into 1 .5ml eppendorf tubes, then lysed by sonication. Samples were then
vortexed immediately before being analyzed for cAMP levels using a direct cyclic AMP
enzyme immunoassay kit according to the manufacturer instructions (Assay Designs Inc).
Briefly, the assay utilizes p-nitrophenyl phosphate as a substrate and a polyclonal
antibody to cAMP to bind, in a competitive manner, the cAMP in sample that has cAMP
covalently attached to it. Reactions were stopped with trisodium phosphate and color
intensity was measured at 405 nm.
Data are expressed as mean values and standard errors of three independent
experiments, each conducted with triplicate samples per treatment group. Statistical
analysis of data was by one-way ANOVA, Tukey-Kramer multiple comparison test and
two-tailed unpaired t-test.
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PKA activation assay
Following incubation of cells with theophylline (10 pM) for 5 minutes to 1 hour
as specified in the figure legends, PKA activity was assayed in cell lysates using a Pep
Tag assay for non-radioactive detection of activated

PKA (Promega Corperation,

Madison, WI, USA), following the instruction of the manufacturer. This assay utilizes
fluorescent substrate for PKA that changes the peptide's net charge upon phosphorylation
of PKA, thus allowing the phosphorylated peptide to migrate to the positive electrode(+),
while the non-phosphorylated peptide migrates to the negative electrode (-). Briefly,
reactions containing a brightly colored fluorescent peptag A l peptide (0.4µg/µl), peptide
protection and PKA activator solutions were incubated in ice for few min before l min
°

incubation at 30 C. After adding samples, reactions were incubated at room temperature
°

°

for 30 min, boiled at 95 C for 10 min, and loaded onto 0.8% agarose gel in 50 mM Tris
HCl (pH 8.0). At this point the qualitative assay is complete, and the protein kinase A
activity in samples was determined by examining the gel under UV lights. Densitometric
analysis of the bands was conducted using NIH Scion software for image quantitation.
Data are expressed as mean values and standard errors of three independent
experiments, each with triplicate samples per treatment group. Statistical analysis of data
was by one-way ANOVA, Tu.key-Kramer multiple comparison test and two-tailed
unpaired t-test.
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Assessment oftotalproteins and phosporylated proteins by Western blotting
To assess the effects of theophylline ( 1 0 pM) on

the expression and

phosphorylation of the mitogen activated protein kinases ERKl /2 or the cAMP response
element binding protein CREB, 500,000 NCI-H322 or SAEC cells were seeded into
culture vessels (100 cm2) containing their respective growth media. When the cells had
reached 60-65% confluence, they were rinsed one time with l X PBS and serum-starved
for 24 hours. Following removal of the media and replacement with fresh low-serum
media, theophylline (10 pM) was added to the culture vessels and cells were incubated
from 5 minutes to 1 hour as detailed in the figure legends. The cultured cells then were
washed once with cold PBS, lysed in 20 mM Tris-base, 200 mM NaCl, 1 M sodium
fluoride. 0.5 M EDTA, 1 00 mM Na3V04 , 100 mM PMSF, 1µ1 pepstatin, 1 µl leupeptin, 1
µI aprotinin, and 0.25 % NP-40. Then, protein samples were denatured by boiling at
°

95 C for 5 min, separated on 10% SDS-PAGE, and transferred to nitrocellulose.
Membranes were blocked with 5% non-fat dry milk, probed with rabbit polyclonal CREB
and

phosphorylated

CREB

antibodies,

respectively,

and

developed

by

chemiluminescence with ECL reagentsMembranes were blocked in 10ml of 5% non-fat
dry milk (Kroger) in l X TBST for 1 hour. Membranes were then incubated over night at
4°C with primary antibodies at a 1 :1000 dilution (rabbit polyclonal for total ERKl/2,
rabbit polyclonal for Thr202/Tyr204 phosphorylated Erk l/2; rabbit polyclonal for total
CREB, mouse monoclonal for SER33

phosphorylated CREB; Cell Signaling

Technology, Beverly, MA). Equal loading of lanes was confirmed by blotting for actin
using mouse actin monoclonal antibody (Sigma-Aldrich Co., St. Louis, MO, USA).
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Data are expressed as mean values and standard errors of three independent
experiments, each conducted with triplicate samples per treatment group. Statistical
analysis of data was by one-way ANOVA, Tukey-Kramer multiple comparison test and
two-tailed unpaired t-test. Following statistical analysis, data were normalized with
controls set as 100% for documentation as column graphs.

Assessment of cell numbers by MTT assay
The effects of theophylline on cell proliferation were assessed by the
colorimetric 3-( 4, 5-dimethyle thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
assay (2) (Sigma-Aldrich Co., St. Louis, MO, USA). Briefly, the MTT test is based on
the NADH-dependent enzymatic reduction of the tetrazolium salt MTT [3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide] in metabolically active cells
but not in dead cells. Cells were seeded into 6-well tissue culture plates (Falcon,
Franklin Lakes, NJ, USA) at a density of 50,000 cells per well for NCI-H322, and
50,000 cells per well for SAEC. The cells were left to grow in complete media at 37°C
with 5% CO2 for 5 hours to attach. The cells were then switched to fresh low serum
media and theophylline was added at the concentrations specified in the figure legend
and incubated for 72 hours. Fresh low serum medium of each cell line and fresh
treatment were added every other day. After treatment for 68 hours 50µ1 of [3-( 4, 5dimethyl thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (0.5mg/ml) was dissolved in
RPMI-1640 with L-glutamine and phenol-free medium (Gibco Invitrogen Corporation,
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Grand Island, N.Y, USA)], added to the medium and incubated at 37°C in the incubator
for another 2-3, allowing for the metabolic conversion of the MTT substrate to blue
formazan. The media were then discarded and 550 µl of Isopropanol (2-propanol UV
cutoff 205 nm, Fisher Scientific, GA, USA) was added to the wells. Absorbances at 570
nm and 630 nm in each well were measured on a micro-ELISA. Data are expressed as
mean values and standard errors ofthree independent experiments, each conducted with
four samples per treatment group. Statistical analysis of data was by one-way ANOV A,
Tu.key-Kramer multiple comparison test and two-tailed unpaired t-test.
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Results
Exposure of the putative cells of origin of pulmonary adenocaricnoma, SAECs,
for ten minutes to theophyHine caused a significant and concentration-dependent increase
in intracellular cAMP as assessed by immunoassay (Figure 1). This response peaked at
the 10, pM concentration a 2.2-fold increase. Similarly, the human PAC cell line NCI
H322 responded with a 2.1-fold increase in intracellular cAMP when exposed to 10 pM
theophylline (Figure 1). The observed stimulation of cAMP was reproducible as assessed
by three independent experiments that yielded similar results, each with three samples per
treatment group. Because cAMP levels peaked in both cell systems after expoure to 1 0
pM theophyHine, this concentration was used in assays for the assessment of PKA
activation and phosphorylation of CREB and ERK.1/2. Statistical evaluation of the data
by one-way ANOVA, Tukey-Kramer multiple comparison test and paired two-tailed t
test established significant differences between control and treatment groups at all
theophyline concentrations tested in both cell systems.
Assessment of PKA activation by a non-radioactive kit that measures the
migration of the phosphorylated peptide to the positive electrode(+), while the non
phosphorylated peptide migrates to the negative electrode (-), revealed a time-dependent
increase in activated PKA of SAECs exposed to theophylline (10 pM; Figure 2) with a
maximum 5-fold increase at the 5 minute time interval (Figure 2). Similarly, the human
PAC cell line NCI-H322 responded to 10 pM of theophylline with a time-dependent
increase of PKA activity that peaked with a 4.97--fold increase at the 15 minute time
interval (Figure 2). In SAECs, the observed increase in PKA activity was highly
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significant at all time interval tested (p< 0.00 1 by one way ANOVA, Tukey-Kramer
multiple comparison test and unpaired, two-tailed t-test from triplicate samples

per

treatment group of three independent experiments). In NCI-H322 cells, no increase in
PKA activity was observed after 5 minutes of exposure to theophylline whereas the
increase in PKA acitity was highly significant (p<0.00 1 ) after expoure for 1 5, 30, or 60
minutes.
The effects of theophylline ( 1 0 pM) on expression levels of the transcription
factor CREB and its phosphorylated form were assessed by Western blot analysis (Figure
3 ). SAECs demonstrated a time-dependent increase in p-CREB protein with the highest
level (5 .35-fold-fold increase) observed after 1 5 minutes of exposure (Figure 3). NCI
H322 cells were similarly responsive to theophylline with a 5 .45-fold increase in p
CREB observed after 1 5 minutes of exposure (Figure 3). In neither cell line did exposure
to theophylline increase the levels of unphosphorylated CREB protein (Figure 3). The
observed increases in p-CREB expression were highly significant in both cell systems at
all time intervals tested

(p<0.001 by one way ANOVA, Tukey-Kramer multiple

comparison test and two-tailed unpaired t-test from mean values and standard errors of
densitometric values from three independent experiments conducted under identical
conditions, each with triplicate samples).
The effects of theophylline ( 1 0 pM) on the mitogen-activated kinases ERKl/2 and
their phosphorylated forms were also assessed by Western blotting. As exemplified in
Figure 4, p-ERKl /2 was significantly increased in SAECs after 5, 1 5 or 30 minutes of
exposure to theophylline with peak values (3 .5-fold increase) at the 5 minute time
interval (Figure 4). The response of the cancer cell line NCI-H322 to theophylline was
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similar, with a 3 .3-fold increase in p-ERK.1 /2 expression after 5 minutes of exposure
(Figure 4). The observed increases in p-ERK.1 /2 in both cell lines cells were highly
significant (p<0.00 1 ) for SAECs at them 5, 1 5 and 30 minute time intervals and for NCI
H322 at all time points tested (one-way ANOVA, Tukey-Kramer multiple comparison
test and two-tailed unpaired t-test from densitometric values of three independent
experiments conducted under identical conditions, each with triplicate samples).
Theophylline did not increase the expression of unphosphorylated ERK. 1/2 protein in
either cell system at any of the time intervals tested.
The potential role of the observed changes in cAMP, PK.A, and phosporylated
proteins on cell proliferation was assessed by MTT assays. In our published studies on
the growth-stimulating effects of P-adrenergic agonists and cAMP on NCI-H322 cells we
used [3H]-thymidine incorporation assays that monitor DNA synthesis ( 1 3 , 1 6). Because
the MTT assay monitors numbers of viable cells which can be influenced by both, cell
proliferation and apoptosis, the results of the MTT assays were verified by [3H]thimidine
incorporation assay with controls versus three concentrations ( 1 pM, 1 0 pM, 1 00 pM) of
theophylline (data not shown). We tested the effects of theophylline on cell numbers in
the MTT assay after 24, 48 or 72 hours of incubation. While the stimulating effects of
theophylline were highly significant at all time intervals tested in SAECs, the responses
after 72 hours of exposure were the most dramatic and are therefore illustrated in Figure
5 . Our data show that theophylline caused a dramatic increase in the numbers of SAECs
particularly at the low concentrations, an effect that peaked with a 2.9-fold increase after
incubation with a 1 pM concentration (Figure 5). Under the condition of our experiments,
the cancer cell line NCI-H322 were less responsive, with a small but significant increase
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in cell numbers at 10 and 100 nM concentrations oftheophylline. The stimulatory effects
of theophylline on cell proliferation in SAECs were highly significant (p< 0.001) while
very significant (p< 0.01) in NCI-H322 cells by one-way ANOVA, Tukey-Kramer
multiple comparison test and two-tailed unpaired t-test.
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Discussion
Theophylline is contained in green tea, black tea and mint tea as well as in a host
of asthma therapeutics, over the counter cold medicines (1 7) and dietary supplements
that target weight loss via green tea extracts. Even though the conflicting data on the
tumor modulating effects of tea (5 , 6) implicate that

ingredients in this family of

beverages may have beneficial effects on some cancers while promoting others, the
potential tumor modulating effects of theophylline have not been given attention in past
research. The discovery that the leading type of lung cancer, PACC, is regulated by a
pathway initiated by �-adrenergic receptors and involving the stimulation of cAMP ( 1 3,
1 4, 1 6, 1 9) strongly suggests that phosphodiesterase inhibitors such as theophylline ,
which increase intracellular levels of cAMP, may act as selective promoters of this cancer
type. In support of this hypothesis, our current data show that theophylline significantly
increased intracellular cAMP, activated PKA, phosphorylated CREB and phosphorylated
ERK.1/2 in SAECs and NCI-H322 cells. SAECs additionally responded with a highly
significant increase in cell number suggestive of increased cell proliferation. The lack of
proliferative response of NCI-H322 cells to theophylline is a reflection of a very strong
autocrine growth stimulation via production of EGF that has developed in this cell line
under prolonged in vitro passages. Unfortunately, early passage material of this cell line
is no longer available.
The growth-stimulating effects of theophylline observed in SAECs and PAC cells
are in accord with published data that have documented a stimulation of cell proliferation
of human PAC cells in vitro in response to agents that increase intracellular cAMP ( 1 3 ,

1 00

1 6). A cancer promoting effect of agents that increase intracellular cAMP has also been
documented in a hamster model of PAC induced by the tobacco-specific carcinogen
NNK ( 1 4, 1 9). By contrast, such agents inhibited the growth of human PAC cells of
alveolar type II cell lineage ( 1 6) or human small cell lung cancer cells (20) and
demonstrated significant cancer preventive effects in a hamster model of NNK-induced
neuroendocrine lung tumors ( 1 9).
Collectively, our current data and published evidence emphasize the fact that
identical pathways can have very different functions in different cell types and in cancers
of different cell lineages. Strategies that target regulatory signal transduction pathways
for the prevention and therapy of cancer have to carefully consider this. Unless suitable
diagnostic tools are developed that identify which signaling pathway is hyperactive in
individual patients, clinical trials aimed at modulating signal transduction will continue to
yield disappointing results.
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Summary
The methy lxanthine theophyHine is contained in tea and in numerous asthma and
cold medications. Theophylline inhibits the enzyme phosphodiesterase, thereby
preventing the intracellular break-down of cAMP. The resulting increase in intracellular
cAMP reduces smooth muscle tone, thus dilating the airways. Epidemiologic studies on
· preventive effects of tea on the development of lung cancer have yielded mixed results,
with some studies demonstrating a reduction in lung cancer risk whereas others showed
evidence for cancer promotion. On the other hand, preclinical studies in mouse models of
lung cancer or in vitro systems have consistently demonstrated strong cancer preventive
effects of tea and of polyphenols contained in tea.
Investigations conducted in our laboratory have recently shown that cell lines
derived from human pulmonary adenocarcinomas of Clara cell lineage (PACC) and
experimentally induced PACCs in a hamster model are under �-adrenergic growth
control. Beta-adrenergic agonists as well as forskolin, which activates cAMP, had strong
growth-promoting effects on human P ACC cells and on the hamster PACCs. The current
project therefore tests the hypothesis that theophylline activates growth-stimulating
signaling in human P ACC cells and their normal cells of origin, small airway epithelial
cells (SAEC).
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APPENDIX
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Figure 1 . Effects of theophylline ( 1 0 minutes) on intracellular cAMP
accumulation in SAEC and NCI-H322 cells. Following a 24 hour starvation
period, the cells were incubated for 1 0 minutes with theophylline at the indicated
concentrations. Analysis of cAMP was by competitive binding assay as outlined
in the Materials and Methods. Bars represent mean values and standard errors of
triplicate samples from three independent experiments expressed as normalized
data (controls were set as 1 00- %). Statistical analysis of data was by one-way
ANOVA, Tukey-Kramer multiple comparison test and two-tailed unpaired t-test.
The increase in intracellular cAMP was significant (p<0.0 1 ) at all theophylline
concentrations tested in both cell systems.
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Figure 2A. Agarose gel exemplifying the effects of theophylline (10 pM
incubated for 5 to 60 minutes) on phosphorylation of PKA in SAECs and NCI
H322 cells. Following a 24 hour starvation period, the cells were exposed to
theophylline for the indicated times. PKA activity was then assayed in cell lysates
using a Pep Tag assay for non- radioactive detection of PKA and the samples
were separated on an 0.8% agarose gel. Phosphorylated peptide migrated towards
the positive electrode (+Ve), while non-phosphorylated peptide migrated towards
the negative electrode (-Ve).
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Figure 2B. Bar graph illustrating densitometry values of the bands in Figure 2A.
Densitometric analysis was performed using the NIH Scion software for image
quantitation. Bars represent normalized (control values set at 100%) mean values
and standard errors of three independent experiments, each with triplicate
samples. Statistical analysis of data was by one-way ANOVA, Tukey-Kramer
multiple comparison test and two-tailed unpaired t-test. The observed increases in
phosphorylated PKA were significant (p<0.001) at all time intervals tested in the
SAECs and after 15, 30 and 60 minutes of exposure in NCI-H322 cells.
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Figure 3A. Western blots exemplifying the effects of theophylline (10 pM) on the
expression of phosphorylated CREB and total CREB protein in SAECs or NCI-H322
cells. Following a 24 hour starvation period, cells were exposed to theophylline for
the time intervals indicated. The bands for p-CREB increased in size and density over
time whereas no increase was observed in the bands for total CREB protein.
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Figure 3B. Bar graph illustrating densitometry values of the bands in Figures 3A.
Densitometric analysis was performed using the NIH Scion software for image
quantitation. Bars represent normalized (control values set at 1 00%) mean values and
standard errors of three independent experiments, each with triplicate samples.
Statistical analysis of data was by one-way ANOVA, Tukey-Kramer multiple
comparison test and two-tailed unpaired t-test. The observed increases in p-CREB
were significant (p<0.00 1 ) in both cell systems at all time intervals tested.
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Figure 4A. Western blots illustrating the effects of theophylline (exposures from 5
minutes to 60 minutes, 1 0 pM) on the expression of ERK.1 /2 and its phosphorylated
form in SAECs and NCI-H322 cells. Cells were exposed to theophylline for the time
intervals indicated after a 24 hour starvation period. The bands for p-ERK 1 /2
increased in size and intensity, an effect that peaked after 5 minutes in both cell
systems whereas the expression of ERK.1/2 did not increase.

1 12

600
500
400
300

�

200

SAEC
NCI-H322

1 00 1
0

0

5

1 5 30

60

Minutes

Figure 4B. Bar graph illustrating densitometry values of the bands in Figure 4A.
Densitometric analysis was performed using the NIH Scion software for image
quantitation. Bars represent normalized (control values set at 1 00%) mean values and
standard errors of three independent experiments, each with triplicate samples.
Statistical analysis of data was by one-way ANOVA, Tu.key-Kramer multiple
comparison test and two-tailed unpaired t-test. The observed increases in p-ERK. 1/2
were significant (p<0.00 1 ) in NCI-H322 cells at all time intervals tested and in
SAECs after 5, 1 5 , and 30 minutes.
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Figure 5. Effects of theophylline ( l pM-1 µM) on cell number in SAEC and NCI
H322 cells as assessed by MTT assay. The cells were left in complete media for 5
hours to attach. The cells were then switched to fresh low serum media (0.05% FBS)
for SAECs and (0. 1 % FBS) for NCI-H322. Cells were then exposed for 72 hours to
theophylline at the concentrations indicated. Bars represent normalized (control
values set at 1 00%) mean values and standard errors of three independent
experiments, each with four samples per group. Statistical analysis of data was by
one-way ANOVA, Tukey-Kramer multiple comparison test and two-tailed unpaired t
test. The observed increases in SAECs were significant (p<0.00 1 ) at concentrations
from 1 pM to 1 0 nM. The PACs were less responsive, with a small but significant
(p<0.0 1 ) increase at the 1 0 and 1 00 nM concentrations.
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